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1. INTRODUCTION
The word menstruation comes from the Greek word menus
meaning both moon and power, and men meaning month. The blood from the womb was
believed to nourish the unborn child and was considered 'mana' or 'breath of life.
One national study found that menstrual disorders were the reason for
19.1% of 20.1 million visits to physician office for gynecologic conditions over a two-year
period. It has long been recognized that thyroid dysfunction may have profound effects on
the female reproductive system. A relationship between the thyroid gland and the gonads
is suggested by the common appearance of goiter during puberty, pregnancy and the
menopause.1 Thyroid disorders are insidious and ubiquitous in their presentation. Their
role has been indicated in a wide spectrum of reproductive disorders ranging from
abnormal sexual development to menstrual irregularities to infertility and premature
menopause.2
In gynecology, 20% women present with abnormal uterine
bleeding.3 The underlying cause of DUB is still uncertain, but in most cases it is
associated with failure of ovulation and is a consequent of hormonal imbalance. Ovarian
dysfunction may be caused by either a primary defect or pathologic lesion within the
ovary itself or it may be secondary to malfunction of other endocrine glands, notably the
hypothalamus, pituitary and thyroid.4
Anovulatory or dysfunctional uterine bleeding includes the
spectrum of abnormal menstrual bleeding patterns that occur in anovulatory women who
2 | P a g e
have no medical illness or pelvic pathology.5 Abnormal uterine bleed includes both DUB
and bleeding from structural causes. Anovulatory DUB is characterized by unpredictable
irregular bleeding and ovulatory DUB is characterized by heavy and regular cycles or
menorrhagia.6 Fibroids, polyps, pregnancy complications, endometrial carcinoma etc
include the structural causes. It can also be caused by contraceptive methods. Systemic
causes include hypothyroidism, coagulation disorders and cirrhosis.7 Bleeding due to a
wide assortment of causes inside and outside the genital tract can masquerade as
anovulatory bleed. Careful menstrual history and examination provides the information
required to differentiate anovulation from other causes. When there is strong suspicion of
pathology or treatment of presumed anovulatory bleed fails, additional evaluation is
recommended.5
Menorrhagia is commonly tackled with hormonal therapy,
curettage and hysterectomy with its attendant morbidity and mortality in many cases of
anaemia, undiagnosed thyroid disease and coagulopathies.8 Recently "occult"
menorrhagia has been found to be an early manifestation of sub clinical hypothyroidism
with the disease becoming symptomatic later.9 The present study is to evaluate thyroid
profile in patients with abnormal uterine bleeding.

Hypothesis & Justification
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2. HYPOTHESIS AND JUSTIFICATION
There is a higher prevalence of hypothyroidism in patients with abnormal
uterine bleeding. According to review of literature there is an association between thyroid
profile and abnormal uterine bleeding. Therefore evaluation of thyroid profile will help in
diagnosis of abnormal thyroid function in patients presenting with menstrual irregularities and
help in treatment of the same. This study that explains the relation between thyroid profile and
abnormal uterine bleeding can be used as a reference for further studies in future.6

Aims and objectives
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3. AIMS AND OBJECTIVES
i. To evaluate and compare the T3, T4 and TSH levels between patients with abnormal
uterine bleeding and controls.
ii. To evaluate and compare the levels of thyroid profile in patients with abnormal uterine
bleeding.

Review of Literature 
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4. REVIEW OF LITERATURE  
Marinal Kanti Kundu. et. al. selected 100 cases of DUB  in their study. 23% had 
thyroid dysfunction, 13% subclinical hypothyroidism, 7% hypothyroidism and 3% 
hyperthyroidism. The study result found polymenorrhoea and menorrhagia as the 
most common forms of DUB.10  
Talasila Sruthi et.al. analysed 100 women presenting with menorrhagia, 11% had 
thyroid disorders, 8% had subclinical hypothyroidism, 2% hypothyroidism and 1%  
hyperthyroidism.11 
Mangala Gowri B. et. al.  Found that in a study population of 170, 132 women had 
normal thyroid status, 30 had hypothyroidism & 5 had subclinical hypothyroidism. 
Eight women had hyperthyroidism.12 
Carlo Saccardi. et. al. Their study hypothesis was based on the double action of 
hypothyroidism and thyroxine intake, in subclinical TSH. Increased levels may be 
due to circadian oscillation that could stimulate the endometrial TSHRs.13 
Anneli Stavreus Evers. et. al. found that thyroid hormone is required for 
implantation, decreasing inflammation of endometrium & embryo development. 
Thyroid diseases often cause  menstrual disturbance and infertility  due to the lack of 
above actions.14 
Anita Choudhary. et. al. showed significant increase in platelet aggregability in the 
study population. Thyroid dysfunction can disturb the physiological process of  
hemostasis .15 
Review of Literature 
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Pushpa Sirichand. et. al. study results found  82% of hypothyroidism, 18% 
hyperthyroidism .Here 88% were married and 12 % were single. Menorrhagia (40%) 
was the most common menstrual problem in the study population.16 
Ajay Kumar. et. al. observed decreased hemoglobin level in hypothyroidism 
patients. Administration of thyroxine increased hemoglobin levels which was 
statistically significant.17 
Shivaleela M Biradar. et. al. selected 100 subjects ,here 50 were women with 
primary infertlity and 50 healthy euthyroid fertile women. The study result showed 
increase in T3 and T4, decrease in TSH level in fertile women compared to the 
healthy women. 42% of the infertile women had thyroid dysfunction.18 
Attia AH. et.al studied forty euthyroid women with menorrhagia and 20 women with 
normal menstrual cycle. Statistically significant differences were observed in the 
thyroid profile on comparison of cases and controls.19 
Jayakumar et.al found that changes in the thyroid profile in relation to menstrual 
pattern were studied in congenital hypothyroidism. This study concluded that patients 
with anaemia and secondary menorrhagia were found to be associated with congenital 
hypothyroidism.20 
Wilansky et. al 67 patients were evaluated for functional status of the thyroid gland 
in yprimary hypothyroidism. Complaints of menorrhagia resolved in 3-6 months 
following administration of L-thyroxine in hypothyroid patients.8 
Chakrabarti Jayita. et. al. Studied 50  women in reproductive age group  with 
menorrhagia. The study results showed hypothyroidism in 20% of study population.21 
Review of Literature 
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Neelu Sharma. et. al. In fifty patients with dysfunctional uterine bleeding (GP-A) in 
reproductive age group presenting with menstrual irregularities like menorrhagia, 
oligomenorrhoea, amenorrhoea, hypomenorrhoea and polymenorrhoea  thyroid 
profile was evaluated and fifty thyroid patients in endocrinology were evaluated  for 
menstrual patterns (GP-B). The study results showed hypothyroidism in 11 (22%) and 
hyperthyroidism in 7 (14%) women in (GP-A).In Group-B 56 % hypothyroid patients 
had disturbed menstrual cycles with associated problems and 62 % of hyperthyroid 
patients were found to have disturbed menstrual cycles ranging from menorrhagia to 
oligomenorrhoea to amenorrhoea.22 
Tjinder Kaur et. al. Studied 100 premenopausal women with DUB by evaluating 
their thyroid status and determining their serum TSH. 14 were hypothyroid, 1 
hyperthyroid and remaining 85% were euthyroid. Out of the 14 hypothyroid women 9 
(64.3%) had menorrhagia, 2 (14.3%) metrorrhagia and 3 (21.4%) had 
oligomenorrhoea, patient with hyperthyroidism were found to have 
hypomenorrhoea.23  
Pahwa Sangeeta et. al. Out of 100 cases, 22 were hypothyroid, 2 hyperthyroid and 
76 euthyroid. 50% had menorrhagia and 75% metropathia haemorrhagica. 78.6 % of 
menorrhagia was seen in  hypothyroid patients and 5.26 % in hyperthyroid patients.24 
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 4.1. PHYSIOLOGY OF MENSTRUATION 
Noyes, Hertig and Rock in 1950 described the cyclical histological changes in the 
endometrium.25 Epithelial glandular cells, stromal-mesenchymal cells: and blood vessels 
of the endometrium cyclically replicate in reproductive-aged women. The superficial two 
thirds of the endometrium is the functionalis layer. It is composed of the deeply situated 
intermediate zone (stratum spongiosum) and a superficial compact zone (stratum 
compactum). It is shed and regenerated from the basalis layer about 400 times in a 
reproductive woman.26 
4.1. a. Endometrial cycle 
4.1. a. i. Proliferative phase 
The first day of a cycle is the first day of menstrual bleed. The functionalis layer 
is fragmented and shed during menstruation and re-epithelialization is started. By fifth 
day epithelilization is completed and vascularization begins.26 Initialy endometrium is 
thin about 2mm. Then the glands are narrow, tubular and are straight and parallel up to 
the surface. Mitotic figures are identified from day 5 and are seen in both epithelium and 
stroma up to day 16-17. The glands progress from a low columnar variety to a 
pseudostratified pattern before ovulation.27 This is dependent on various estrogen 
regulated growth factors; epithelial growth by EGF and TGF- , stromal growth by 
paracrine and autocrine action of estrogen and also fibroblast growth factor-9 and vessels 
get elongated under the influence of VEGF.28,29 The glands then become widely spread 
Review of Literature 
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and stroma loose compared to the basal layer. The cells develop numerous microvilli that 
increase the surface area and cilia help in propulsion of endometrial secretion.30 
4.1. a. ii. Secretory phase 
Endometrial dating is a process of determining the day of menstrual cycle using 
histology. It is easier in the constant secretory phase than the variable proliferative phase. 
Now progesterone acts on an estrogen primed endometrium.  
Day 17 endometrium shows accumulation of glycogen in the basal region of the glands, 
showing sub nuclear vacuoles and psuedostratification. This indicates ovulation has 
occurred.31 Day 18: Vacuoles move to the apical region of the then, non ciliated cells.  
Day 19:  Cells begin to secrete glycoprotein and mucopolysaccharides into the lumen.32 
Mitosis ceases due to the antagonizing action of rising levels of progesterone. Type 2 17 
 hydroxy steroid converts the estradiol present to inactive estrone.33 Dating from mid to 
late secretory phase now depends on the structure of stroma. Day 21-24: Stroma becomes 
edematous. 
Day 22-25: Stromal cells around the spiral arterioles begin to enlarge and stromal mitosis 
begins. The pre-decidual transformation of the functionalis layer heralds the window 
period for implantation. These changes are apt to receive a blastocyst. The glands 
develop extensive coiling and luminal secretions, the microvilli and cilia disappear and 
apical pinopodes appear. The surface glycocalyx undergoes changes. 
Review of Literature 
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Day 23-28: Shows predecidual cells surrounding the spiral arterioles. Day 24 is 
characterized by a pattern of decidual cuffing. 
Changes in the vascularity are as follows spiral arterioles lengthen at an 
appreciably higher rate than the growth of endometrium this leads to more and more 
coiling of the already spiraling vessels. Perrot Applant demonstrated estrogen and 
progesterone receptors in smooth muscles of uterus and spiral arterioles. They mediate 
rapid angiogenesis through the production of VEGF by stromal and glandular 
epithelium.34 
4.1. a. iii.  Menstruation 
If corpus luteum is rescued and progesterone production continues, 
decidualization continues, but if luteolysis is initiated, there will be cessation of glandular 
secretion and irregular breakdown of the functionalis layer. The sex steroids are 
withdrawn leading to profound vasospasm of spiral arterioles leading to endometrial 
ischemia a day or two before menses and stromal infiltration of inflammatory cells. The 
invading leukocytes secrete members of matrix metalloproteinases, which along with 
local proteolytic enzymes help in tissue breakdown. PGF2  produced causes further 
arteriolar vasospasm, endometrial ischemia and myometrial contractions.26 
Review of Literature 
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4.1. b The ovarian cycle 
4.1. b. i. Follicular phase 
4.1. b. i. a) Primordial follicle  
Primordial germs cells develop from the endoderm of yolk sac, hindgut and 
allantois of the embryo. They migrate to the genital ridge by 5-6 weeks. In fetal life the 
influence of HCG induces the proliferation of ovarian germ cells. It reaches a maximum 
number of 6-7 million by around 20 weeks of gestation. Only 2 million will be present at 
birth and only 3 hundred thousand at puberty. Only 400 will ovulate. Oogonia then enters 
meosis-I. A half million oogonia get arrested in the diplotene stage of prophase of 
meosis-I after birth. This step requires the action of ovarian determinant gene located on 
both arms of X-chromosomes and autosomes as well. A primordial follicle consists of 
this arrested oocyte and a single layer of granulosa cells. Follicles continue to grow and 
undergo atresia in all physiological circumstances.35 This process is not interrupted by 
pregnancy or periods of anovulation and ovulation. 
The mechanism determining the process of selection of follicles for a cycle is 
unknown. The follicle that has a timely match of readiness and tropic hormone 
stimulation may be the one destined for the lead role in a particular cycle. The early part 
of follicular growth is independent of any influence by gonadotrophins.5 About three 
months before ovulation around 300 follicles are recruited for development. Out of these 
30 become gonadotrophin dependent and start growing rapidly from the beginning of the 
Review of Literature 
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menstrual cycle.36 If the follicles are not rescued by FSH they receed back to a process of 
atresia. 
The molecular events that regulate the growth of the primordial follicle include a 
variety of locally produced and regulated factors. Growth of primordial follicle is 
upregulated by activin and down regulated by inhibin and their relative concentrations 
determine the size of the ovarian follicular pool in the fetus. AMH inhibits the growth of 
primordial follicle and bone morphogenic protein promotes growth.  Neurotropic factors 
like NGF, BDNF, NT-3 and NT-4/5 also play a role. The oocyte is linked to the 
granulosa cells by gap junctions; they allow transport of ions, metabolites, cholesterol 
and C-AMP between granulosa cells and the developing oocyte. Gap junctions are 
formed by proteins known as connexins or GJAs. Expression of these proteins is 
upregulated by FSH and down regulated by LH. Gap junctions continue to act within the 
corpus luteum too. 
As the corpus luteum from the previous cycle shuts down and all the luteal 
estrogen, progesterone and inhibin-A levels fall, FSH increases. FSH stimulates follicular 
growth and the cuboidal granulosa cells of the primordial follicle multiply to 
approximately 15 cells and it becomes the PRIMARY FOLLICLE. Granulosa cells are 
separated from the stroma by the basal lamina. Surrounding stromal cells also 
differentiate into concentric layers. When 3-6 layers of granulosa cells are formed, the 
stromal cells closer to the basal lamina differentiate into the theca interna and the outer 
portion into theca externa.5 
Review of Literature 
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4.1. b. i. b) Preantral follicle 
The oocyte then enlarges and gets surrounded by a glycoprotein membrane 
known as the zona pellucida which separates it from the granulosa cells. Estrogens are 
produced by the action of aromatase enzyme complex. FSH binds to certain protein 
receptors on the preantral granulosa cells and induces aromatization. It helps in creating 
an estrogenic micro environment.35
4.1. b. i. c) Secondary follicles or the antral follicle 
Under the influence of estrogen and FSH there is increased production of 
follicular fluid which accumulates in the intercellular spaces of the granulosa cells. They 
coalesce to form the fluid filled antrum. The granulosa cells surrounding the oocyte 
forms the cumlus oophorous. This fluid contains hormones, cytokines and growth 
factors that are necessary for the orderly maturation of the oocyte and the surrounding 
cells. In the presence of FSH, estrogen becomes the predominant component of antral 
fluid, the concentrations of which are much more than the circulating estrogen. In 
contrast an androgenic microenvironment antagonizes proliferation of granulosa cells 
and further leads to follicular atresia.5, 35 
 Two cell Two gonadotropin theory 
The granulosa cells do not have several enzymes that play a role in the early part 
of steroidogenesis and therefore have to dependent on a supply of androgens. Androgens 
are produced as a result of stimulation by LH rather than FSH. At this stage it is the theca 
Review of Literature 
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cells and not the granulosa cells that have maximum number of LH receptors.37 
Therefore, LH stimulates theca cells to produce androgens, mainly androstenedione. This 
is then transported to the granulosa cells, where FSH stimulates the action of the 
aromatase enzyme complex and estrogen is produced. The estrogenic microenvironment 
thus created in the antral fluid is responsible for the growth and nutrition of the oocyte .38 
The genes in the theca cells coding for LH receptors are, P450 scc and 3-  hydroxy 
steroid dehydrogenase. LH regulates the entry of LDL cholesterol into mitochondria for 
steroidogenesis. But the granulosa cells utilize HDL, in a different pathway only after 
lutenization. The theca cells express P450 c17 the rate limiting enzyme for synthesis of 
androgens. Granulosa cells do not have this enzyme. Thus granulosa cells are dependent 
on theca cells for their androgen supply. Theca cells express only P450c17 and granulosa 
cells express only P450 arom (the aromatase enzyme). This confirms the Two cell Two 
gonadotrophin theory.5  
Both FSH and estrogen together have the following effects  
i) Stimulate further estrogen production 
ii) FSH receptor synthesis and expression  
iii) Granulosa cell proliferation and differentiation. 
Androgens have two positive feedback roles in the ovary, they are  
i) Promoting proliferation of granulosa cells and enhancing aromatase activity. 
ii) Inhibition of programmed cell death.39 
Review of Literature 
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The rising peripheral estrogen levels produce the following effects  
a) Negative feedback on the hypothalamus and pituitary to decrease the 
      production of FSH.27 
b) It stimulates the production of inhibin-B which also inhibits the production of  
     FSH. 
The falling FSH level is a threat to continued follicular growth. Those follicles 
with the maximum number of FSH receptors bind most of the diminishing FSH. Thus, 
that follicle with the richest estrogenic microenviornment and the maximum FSH 
receptors (Follicle with maximum rate of granulosa cell proliferation) becomes the 
dominant follicle.40 
There are other local autocrine and paracrine mechanisms acting in the selection 
of a dominant follicle. 
a) The TNF produced by the granulosa cells inhibits FSH induced estradiol secretion 
everywhere except in the dominant follicle.  
b) AMH suppresses the growth of lesser follicles, but not the dominant follicle. 
c) By 9th day vascularity from these theca cells becomes double fold and most of 
    the secreted gonadotropins reach the dominant follicle in spite of a falling level 
    of gonadotrophins.5 
Four feedback mechanisms of gonadotrophin secretion 
1. The long acting negative feedback mechanism:-The rising levels of estrogen produced 
by the graffian follicles, inhibits a further rise in FSH levels leading to inhibition of 
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other developing follicles. This action is mainly mediated by decreasing GnRH 
secretion in the hypothalamus. There may be a direct pituitary effect too, but to a 
lesser extent. 
2. The long acting positive feedback mechanism-as estrogen levels rise, they eventually 
reach a sufficiently high level that stimulates the LH production and to a lesser extent 
the FSH production (The biphasic effect of estrogen - low levels of estrogen inhibits 
LH whereas at high levels it enhances LH secretion). This surge in hormone levels 
results in ovulation. This feedback mechanism, mainly acts at the pituitary level and to 
a lesser extent at the hypothalamus. 
Ovulation causes a temporary fall in the estrogen production, which shuts down the 
positive feedback effect but maintains the negative feedback effect therefore FSH and 
LH remains reduced until corpus luteum fails and estrogen and progesterone wanes. 
The hypothalamus, and to a lesser extent the pituitary are released from the inhibitory 
effect and FSH levels rise again in the new cycle. 
3. The short acting feedback mechanism-the increasing secretion of FSH and LH by 
pituitary exerts negative feedback effect on the hypothalamic secretion of GnRH. 
4. An ultra short acting feedback mechanism is also present which involves the self 
inhibition of hypothalamic regulating hormones as their levels rise. 
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Figure-1: Hypothalamo-pituitary ovarian axis 
    The positive feedback effect requires a sustained high level of 
estrogen about 200pg/ml for more than 48 hrs. This leads to an LH surge. Simultaneously 
the local FSH- estrogen interaction increases the number of LH receptors on granulosa 
cells. The peaking of LH hormone results in initiation of ovulation, production of 
progesterone and luteinisation of granulosa cells. This occurs 34-36 hours after initial rise 
of LH and 10-12 hrs after the surge. 
Review of Literature 
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There are other granulosa derived peptides playing a role in the pituitary feedback 
mechanisms. They are the inhibins and activins. The Inhibin-B acts in the follicular phase 
and Inhibin-A in the luteal phase. Both, inhibin A and B,inhibit  FSH  synthesis and 
release. Activin stimulates pituitary to release FSH and enhances its action on the ovary. 
Some other intra ovarian regulators that promote ovulation are Follistatin, IGF-1, EGF, 
FGF, TGF  and , Interleukin 1, OMI and rennin-angiotensin.27 
4.1. b. ii Ovulation 
The arrested meosis restarts and the first polar body is extruded. The secondary 
oocyte immediately enters the second meiotic division and remains in metaphase until 
fertilization .The growing follicle reaches a size of about 2-3 cm in diameter; the 
dominant follicle forms a protrusion, the stigma, on the surface of ovary. The cell layers 
rupture and the ovum, surrounded by the corona radiata of granulosa cells, are released. 
The process takes place over a period of two mintues. The process is not an instantaneous 
rupture due to rise in intra follicular fluid level but a process of slow extrusion.36 This is 
brought about by an increased distensibilty of the follicle wall and the prostaglandins 
synthesis by granulosa cells which causes the release of collagenases, lysosomes and 
plasminogen activator, leading to the erosion in the surface of ovary  The main 
prostaglandin involved in ovulation is PGI2 (Prostocyclin).35 The LH surge is responsible 
for  prostaglandin production, early progesterone secretion, resumption of  meosis and  a 
decrease in the affinity of gonadotrophin receptors causing desensitisation to LH and also 
a transient decrease in estrogen leading to luteinisation.36 
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4. 1. b. iii. Luteal phase 
    Structure of corpus luteum-after ovulation the granulosa cells of the follicle take 
up lipids and a yellow luteal pigment gets deposited in them. These luteal cells produce 
progesterone. Here the basement membrane of the corpus luteum degenerates and 
proliferating blood vessels invade them. The luteal cells in addition to progesterone 
produce significant quantities of estrogen and Inhibin-A. The corpus luteal steroids 
estradiol and progesterone have a negative central feedback on the hypothalamus and 
pituitary which causes decrease in the FSH and LH secretion. The decreasing levels of 
Gonadotrophins s lead to no further follicular development. Inhibin-A secreted in luteal 
phase also inhibits FSH. Because of the falling levels of LH, the corpus luteal function 
diminishes progressively after 12-16 days and thus forms the scar like corpora albicans. 
The exact mechanism of luteolysis is not known. The regression of the corpus luteum 
leads to a fall in the sex steroids. This causes the withdrawal of the negative feedback 
effect on gonadotrophin secretion; FSH and LH begins to rise again and a new cohort is 
recruited.27,41 
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Figures-2: Physiology of menstruation  
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4.2. Normal menstrual bleeding 
  Among the different hormones acting on the endometrium, it is the action of 
estrogen and progesterone together that produces the most stable endometrium. Their 
combined withdrawal produces the most consistent menstrual characteristics. Most 
ovulatory women have a volume, pattern and duration of flow that they recognize as 
their own and are often accompanied by an equally consistent and predictable 
premenstrual molimina (breast tenderness, bloating and mood swings)  
Variations in flow and cycle length are common at the extremes of reproductive 
age group.  Cycles are often irregular during first 12-18 months after menarche due to 
immaturity of hypothalamo-pituitary ovarian axis. For the first 5-7 years after 
menarche cycles remain relatively long, then decreases gradually in length and 
becomes more regular.  
In reproductive years, the overall cycle length and variability decreases and is 
lowest at 40-42 years. 8-10 years before menopause cycle length and variability 
increases and ovulation becomes irregular and infrequent. Variations in cycle length 
reflect the difference in length of the follicular phase. Few years after menarche, the 
luteal phase becomes extremely consistent about 13-15 days duration.  
Most women have cycles that last from 24-35 days, but at least 20% of women 
experience irregular cycles. Usual duration of flow is 4-6 days, but approximately 3% 
have as less as 2 days and many upto7 days. Average volume of blood loss is 30 ml, 
greater than 80 ml being abnormal. Flow can be excessive without being abnormally 
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long, because most of the blood loss occurs in the first three days. Any deviation in 
the aforementioned patterns deserves evaluation. 
4.2. a. Mechanisms involved in controlling onset and cessation of normal 
menstruation 
Basically normal menstruation was described as the ischemic necrosis of the 
endometrium caused by vasoconstriction of spiral arterioles in the basal layer, due to 
withdrawal of steroid hormones. Towards the end of menstruation there would be 
longer and intense waves of vasoconstriction; along with coagulation due to vascular 
stasis, endometrial collapse and lastly rapid re-epithelialization by estrogen from the 
new follicles. 
Recent perfusion studies do not support the classic hypoxia theory. Histology 
demonstrates the early endometrium as having focal necrosis, inflammation and 
coagulation, than a diffuse hyalinization or a coagulation necrosis that would be seen 
in hypoxia and vasoconstriction.  
Now the central theme of the new model is, enzymatic autodigestion of the 
functional layer and the sub surface capillaries, possibly extending up to the spiral 
arterioles in the basal layer. The classical mechanisms towards the end of 
menstruation involving coagulation, local vasoconstriction and re-epithelialization are 
unchanged. 
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Enzymatic degradation involves the release of intracellular lysosomal enzymes, 
proteases from inflammatory cells and action of matrix metalloproteinases, all 
triggered by estrogen progesterone withdrawal. In the early secretory phase, acid 
phosphatase and other proteolytic enzymes within the intracellular lysosomes are 
inhibited by progesterone, through stabilization of lysosomal membranes. When 
hormone levels fall they destabilize, thus releasing the enzymes into the cytoplasm of 
the epithelial, stromal, and endothelial cells and their intercellular spaces digesting 
the surface membranes and intercellular bridges (desmosomes). In vascular 
endothelium it results in platelet deposition, prostaglandin release, thrombosis, 
extravasation of red blood cells and tissue necrosis. Endometrial cells have the 
capacity to synthesize certain chemokines (IL-8), which is kept inhibited by 
progesterone. When progestrone levels fall, the chemokines are released and leads to 
a recruitment of inflammatory cells. These cells also produce a wide variety of 
enzymes like matrix metalloproteinases (collagenases, gelatinases and stromolysins) 
that contribute to the process of degradation. Progesterone inhibits endometrial matrix 
metalloproteinases through the action of TGF- . Progesterone withdrawal leads to its 
activation.  
Progressive enzymatic degradation of endometrium leads to disruption of 
subsurface capillaries and venous system, which leads to interstitial hemorrhage and 
as surface membrane dissolves blood escapes into the uterine cavity. It also extends 
up to the deepest functional layer, leading to rupture of basal arterioles.  
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Menstrual fluid is comprised of endometrium rich in inflammatory infiltrate, red 
blood cells and proteolytic enzymes. Clotting of menstrual blood is prevented mainly 
by the action of plasmin, derived from its precursor plasminogen. The volume of 
menstrual blood loss is controlled by the balance between local- fibrinolytic and 
clotting mechanisms. Endometrial stromal cell tissue factor and  plasminogen 
activator inhibitor (PAI-I) promote clotting. Early in menstruation intravascular 
platelet plugs and thrombi formation limits the blood loss. The cessation of menstrual 
bleed involves vasoconstriction of spiral arterioles, and also maybe of the radial 
arterioles in the superficial myometrium. The menstrual endometrium produces high 
concentrations of endothelins and prostaglandins, which cause intense 
vasoconstriction. PGF2  is responsible for the myometrial contractions associated 
with this. Finally, surface re-epithelialization begining at the mouth of endometrial 
glands, spreading outward contributes to hemostasis. By the 5th day these scattered 
areas of epithelial proliferation converge and fuse. The stroma regenerates from stem 
cells located in the basal layer of endometrium. 
4.3. Pathophysiology of abnormal uterine bleeding   
Anovulatory bleeding results from estrogen withdrawal accompanying the 
transient fall in estrogen caused by the regression of a follicular cohort. Otherwise it 
can be an estrogen break through bleed, from the focal breakthrough of an 
overgrown and fragile endometrium. Heaviest anovulatory bleed occurs in women 
with sustained elevated serum estrogen levels, women with PCOD, obese women, 
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post menarcheal girls and perimenopausal women. Ovarian hormone production and 
endometrial stimulation is unpredictable and disorganized in anovulatory bleeds. The 
anovulatory female is always in the follicular (proliferative phase) of endometrial 
cycle. As no ovulation has occurred, there is no luteal phase or secretory phase. 
Estrogen levels constantly fluctuate; rises and falls with the growth of each new 
cohort of follicles, but it ultimately loses its momentum and sooner or later lapses 
into atersia. 
Uninterrupted estrogen growth stimulates the endometrium to proliferate to 
abnormal heights, but it becomes fragile. In the absence of the growth limiting and 
organizing effects of progesterone, there is an absence of the stromal support 
structure that provides stability. Few focal areas break down and bleed and later heal 
under the influence of continued estrogen production, followed by other areas. 
Persistent proliferative endometrium shows focal areas of stromal breakdown, pools 
of extravasated red blood cells, capillary platelet and fibrin thrombi and ball like 
aggregates of tightly packed stromal cells with a cap of hypertrophied epithelium. 
Venous capillaries are dilated and increased to form abnormal irregular channels, 
with abnormal ultra structural elements predisposing to fragility. Available evidence 
shows that, anovulatory bleeding results from an increased density of abnormal 
fragile vasculature, release of lysosomal proteolytic enzymes from epithelial, stromal 
and inflammatory cells. There is a local release of prostaglandins with more affinity 
for the vasodilatory PGE2 than the vasoconstrictor PGF2 . Molecules like perforins 
inhibit capillary plug formation and further degrade capillary network. 
Review of Literature 
26 | P a g e
Vasoconstriction of the vessels of basal endometrium and superficial myometrium 
does not occur because tissue loss is only superficial, focal and does not reach the 
basal layer where denudation causes intense vasoconstriction. The final mechanism 
of epithelial reconstruction does not occur. The epithelial repair is only focal and it 
results in a constantly changing patchwork of small repairs, instead of organized 
well structured remodeling.5 
4.4. Abnormal uterine bleeding 
Abnormal uterine bleeding includes all abnormal menstrual patterns including 
spotting between periods, excessive bleeding during menstruation, prolonged 
duration of flow, menstrual cycles less than 21 days or more than 35 days and 
frequent cycles, as well as the absence of menstruation. 
4.4. a. The types of abnormal menstrual patterns are 
i.  Menorrhagia: Menstrual cycles & menstruation occurring on a normal schedule, 
   but with excessive flow and prolonged duration of flow >7 days. 
ii. Metrorrhagia: Menstruation occurring at irregular intervals. The amount of 
    blood loss & the number of days of vaginal bleed are not excessive in these 
    patients. 
iii. Menometrorrhagia: Characterized by irregular menstruation along with excessive 
bleed. 
iv. Polymenorrhea:  Menstrual cycle is less than 21 days long. 
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v. Dysfunctional uterine bleeding: Is a diagnosis given when there is no apparent 
     cause for abnormal uterine bleeding. A diagnosis of DUB is made after excluding  
    all other anatomic causes of abnormal uterine bleeding. 
vi. Oligomenorrhoea: Menstrual cycles that occur more than 35 days apart.  
vii. Amenorrhoea:  Absence of menstruation. 
a) Primary amenorrhea: when menstruation has not started by the age of 16 years. 
b) Secondary amenorrhea: when menstruation has begun but has later ceased. 
viii. Intermenstrual uterine bleeding: Vaginal bleeding (or) spotting that occurs 
between  normal menstrual periods.42, 43,44 
Due to the confusing nomenclature, lack of standardization of investigation and 
characterization of etiologies the proper management of abnormal uterine bleeding 
among non gravid women has been greatly affected. There may be a variety of 
potential causes coexisting in the same individual and on the contrary many entities 
that often could contribute to AUB, may be asymptomatic in the particular 
individual.45 
Therefore the International Federation of Gynecology and Obstetrics (FIGO) has 
brought out a new classification system based on contributions from an international 
group of clinicians and investigators from 17 countries and 6 continents. There was a 
unanimous decision to discard the term dysfunctional uterine bleeding.46 
It was voted by a majority that the term coagulopathy, endometrial 
dysfunction and ovulatory disorders should replace the term dysfunctional uterine 
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bleeding. So also, the term menorrhagia should be replaced by heavy menstrual 
bleed.47,48 
.4.4.b. Acute, chronic and intermenstrual AUB 
 In the meeting in Cape Town in 2009, chronic AUB was defined as bleeding 
from corpus that is abnormal in volume, timing and/ or regularity and is present for 
the major part of last six months. Acute AUB was defined as an episode of heavy 
bleeding that is of sufficient quantity to require immediate intervention to prevent 
further blood loss.49 It can be superimposed on a chronic AUB or can occur without 
a prior history. Intermenstrual bleeding (IMD) occurs between clearly defined 
predictable and cyclical menses. It can occur randomly or may be predictable 
occurring at the same day in each cycle. This word would replace the term 
metrorrhagia.  
   There is a confusion regarding the exact meaning of the traditional terms, with 
different definitions followed by different authors in different countries. Sometimes 
the pattern of abnormal uterine bleed might not fall into any of the standard 
traditional terminologies and thus, will impair proper communication among health 
care providers.  
  Recommendations arising from an international consensus conference proposed 
terms to describe the most important features of menstrual bleeding during the 
reproductive years. Although the effort to simplify and standardize the terminologies 
of AUB is laudable a new nomenclature would take time to be accepted and adopted 
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by clinicians because however confusing the traditional terms are, they are firmly 
entrenched.5  
Table-1: The proposed new terms by authors Fraser IS, Critchley HO and 
                Munro MG46 
Characteristics  Descriptive Terms Normal Limits  
Frequency on menses  Frequent < 24 days 
Normal 24-38 Days 
Infrequent > 38 days 
Regularity  
(cycle to cycle - variation) 
Absent ---- 
Regular +/- 2-20 days 
Irregular > 20 days 
Duration of flow  Prolonged >8 days 
Normal 4-8 days 
Shortened <4 days 
Volume of monthly blood loss Heavy >80ml 
Normal 5-80ml 
Light <5ml 
 
4.4. c. The new proposed FIGO classification for abnormal uterine bleeding 
There are 9 main categories arranged according to the acronym PALM-COEIN
The PALM group has structural entities that can be measured by imaging 
techniques or histopathology and the COEIN group has non structural entities that cannot 
be defined by either imaging or histopathology. 
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Table-2: PALM-COEIN classification of abnormal uterine bleeding  
PALM  COEIN 
Polyp Coagulopathy 
Adenomyosis Ovulatory dysfunction 
Leiomyoma Submucosal Endometrial 
Other 
Malignancy and 
hyperplasia
 
 
Iatrogenic 
Not yet classified 
 
The term DUB has been abandoned and not included in the system. The women, 
who would fall under this group, usually have one or more factors of coagulopathy, 
disorders of ovulation or a primary or secondary disturbance in local endometrial 
hemostasis. This system was formed taking into consideration the fact that, any patient 
would have one or more entities contributing to AUB and that sometimes definable 
entities like adenomyosis, polyps and myomas may be asymptomatic and do not 
contribute to the presenting symptoms at all. 
Polyp (AUB - P) 
This includes epithelial proliferation comprising of variable, glandular, vascular, 
fibromuscular and connective tissue component. They are usually benign. They are 
classified as being either present or absent, using one or a combination of imaging 
techniques with or without histopathology. Here polypoid appearing endometrium is 
excluded from this category. 
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Adenomyosis (AUB- A) 
The prevalence of this condition is 5-7%. The diagnosis of adenomyosis is based 
on sonographic and MRI based diagnostic criteria. Sonographic appearance is based on 
the presence of heterotropic endometrial tissue in myometrium and is associated with 
myometrial hypertrophy. 
Leiomyoma (AUB - L) 
These are Benign fibromuscular tumors of myometrium, they are classified in the 
following manner:-  
i) Primary classification system:  The presence or absence of one or more 
leiomyomas irrespective of location and size based on a sonographic examination.  
ii) Secondary classification system: Leimyoma involving endometrium, (SM) - 
submucosal is differentiated from others (O).  
iii) Tertiary classification system (ESHRE SYSTEM): Based on the classification 
proposed by Wamsteker et.al. 
Malignancy and hyperplasia (AUB - M) 
They may be the cause of AUB or may be found in association with AUB and 
should be found in all women in the reproductive age group.  
Coagulopathy (AUB - C) 
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Studies show that approximately 13 % women with heavy menstrual bleed have 
biochemically detectable disorders of hemostasis mostly Von Willebrand disease. It is not 
clearly defined as to how often they contribute to the genesis of AUB, or how often they 
are minimally symptomatic or asymptomatic. The heavy menstrual bleed associated with 
chronic anticoagulation is classified under this group  
Ovulatory dysfunction (AUB-O) 
This may present as a spectrum of abnormalities ranging from amenorrhoea, 
through infrequent and light bleeding to attacks of unpredictable extremely heavy 
menstrual bleed requiring intervention. These may be related to the absence of production 
of progesterone by corpus luteum in every cycle. And in later years is related to the 
disturbed ovulations. They are termed as luteal out-of-phase events. 
Many of the ovulatory disorders may be due to endocrinopathies like PCOD, 
hypothyroidism, hyperprolactenemia, weight loss and obesity, mental stress or extreme 
exercise. It can be due to gonadal steroids or drugs affecting dopamine metabolism. It is 
frequently seen that the unexplained ovulatory disorders occurs at extremes of age - 
adolescence / perimenopausal. 
Endometrial (AUB-E) 
          This occurs in cyclical menstrual bleed in the ovulatory cycles, when no other 
definable causes are identified and is due to a primary disorder of the endometrium. If the 
symptom is heavy menstrual bleed it may be due to an impairment of the local 
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endometrial hemostasis system. There may be deficiency in the production of local 
vasoconstrictors such as endothelin-1, PGF2  or may be due to an excessive production of 
plasminogen activator (PA) leading to lysis of endometrial clot or increased production of 
vasodilators like PGE2 and prostacyclin.  
It may also present as intermenstrual bleeding or prolonged bleeding. Prolonged 
bleeding may be due to a deficiency in molecular mechanisms of endometrial repair. It 
may be secondary to endometrial inflammation or infection, local inflammatory response 
or an aberration in endometrial vasculogenesis. There are data indicating an association 
between subclinical chlamydial infections with abnormal uterine bleeding. Diagnosis of 
endometrial disorders should be by a process of exclusion.  
IATROGENIC (AUB-I) 
This includes intrauterine devices and pharmacological agents that affects the 
endometrium, interferes with coagulation mechanism and influences the control of 
ovulation. Unscheduled endometrial bleed due to use of gonadal steroids is termed as 
break through bleeding. A single agent or combination gonadal steroid affect the 
hypothalamo-pituitary-ovarian axis and also has a direct effect on the endometrium. 
When continuous combination pills are given the patient has complete amenorrhoea. 
Here, any bleed is classified as breakthrough bleeding. This occurs because of a 
inadequate suppression of FSH with development of follicles that produce estradiol, 
irregular stimulation of the endometrium occurs leading to breakthrough bleeding. Other 
causes include intake of drugs that  are hepatic enzyme (Cytochrome P450) inducers like 
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anticonvulsants and antibiotics, spotting caused by LNG-IUCD, drugs that inhibit  
dopamine metabolism and  disturbing ovulation causing hyperprolactinemia,for example 
tricycle antidepressants and phenothiazines  and last of all AUB is seen associated with 
the use of warfarin, heparin and low molecular weight heparin through impairment of 
vascular plug formation in the spiral arteries (but the this is to be included in the category 
AUB-C). 
Not yet classified (AUB-N) 
This group included many of the poorly defined conditions like- chronic 
endometritis, myometrial hyperplasia and arterio venous malformations. It also includes 
conditions in which further biochemical and molecular biological assays are required for 
a clear definition. 
4.4. d. NOTATION 
AUB may be caused by 1 or more causes in a particular individual. Therefore a 
system has to be developed to categorize and include all of it in the same individual. This 
simulates the TNM classification of tumors. The presence or absence of an entity in the 
PALM COEIN system is designated as 1 or 0and not yet assessed as ?. 
Eg. AUB   P0   A 0 L1(SM) M 0 C 0 O 1 E 0 I 0 N0 - this patient has a disorder of ovulation 
      and type 2 leiomyoma and no other abnormality. 
AUB P0 A 0 L 0   M0 - C 0 O 0 E 1 I 0 N0 - This patient has no abnormality other than 
endometrial causes. 
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Image-3: PALM COEIN Notation50 
 
4.4. e. Guidelines for investigations 
4.4. e .i. General assessment 
   A careful examination to ensure that the bleeding is not from a 
undiagnosed pregnancy and is from the cervical canal rather than from another location. 
Patient should be evaluated for anaemia with a hemoglobin or hematocrit. A full blood 
count including platelet count should be done. Then the clinician should proceed 
systematically and assess each component of the classification system.  
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4.4. e. ii. Determination of ovulatory status  
Abnormal bleeding due to ovulatory disorders is associated with irregular timing 
and irregular flow and intermittent episodes of amenorrhoea. Further confirmation of 
ovulatory status can be done by measuring serum progesterone or a timed endometrial 
biopsy.51  
4.4. e. iii. Screening for disorders of Hemostasis 
Initial screening should be by a structured history. It has 90% sensitivity. Positive 
screen comprises of any one of the following 
1. Heavy menstrual bleeding since menarche 
2. One of the following  
a) Post partum hemorrhage 
b) Surgery related bleeding 
c) Bleeding due to dental procedures 
3. Two or more of the following symptoms 
a) Bruising once or two times per month 
b) Epistaxis once or twice per month 
c) Frequent bleeding from gums 
d) Family history of similar bleeding symptoms 
Patients with positive screen are further evaluated with assays for Von Willibrand 
factor, ristocetin and other assays. Patient is then referred to a hematologist.52 
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4.4. e. iv.  Evaluation of endometrium  
All patients with AUB do not require endometrial sampling. Patients are selected 
based on a combination of factors reflecting the risk of atypical hyperplasia or carcinoma. 
Factors like age, personal and genetic risk of carcinoma and transvaginal scan for 
endometrial thickness are taken into consideration.53 Sampling is strongly recommended 
for women above 45 years.54 Persistent unexplained / inadequately treated abnormal 
uterine bleed requires sampling, preferably along with hysteroscopic evaluation. It is also 
recommended to consider screening for Chlamydia in symptomatic patients.55  
4.4. e. v. Evaluation of the structure of endometrial cavity  
It should be done using a transvaginal ultrasound. To detect polyps and 
submucosal leiomyomas, ideally it should be the first screening tool. With good 
ultrasound images and with the absence of polyps or myomas the uterine cavity may be 
considered normal and as having no lesions contributing to AUB.  
If imaging shows polyps or myomas encroaching endometrial cavity, or if the 
imaging is suboptimal, more sensitive imaging techniques are recommended. They are 
SIS-SALINE infusion sonography / hysterosonography / hysteroscopy. 
In virgins, there is a role for MRI. With this the AUB  P or AUB  LSM is 
diagnosed. 
 
 
Review of Literature 
38 | P a g e
Image-4: Saline infusion Sonography  
 
4.4. e. v. Evaluation of myometrium  
A combination of transvaginal ultrasound and a transabdominal ultrasound is used 
to identify any leiomyomas and the AUB is classified as L1. If this combination plus sis or 
hysteroscopy fails to identify any myoma then patient is categorized as L0. If myoma is 
present a secondary classification is done using a combination of TVUS, SIS and M.R.I. 
Then a tertiary classification determining the relationship of leiomyoma with 
endometrium, myometrium and serosa is done.50 Presence or absence of adenomyosis 
should be made out. MRI is a better investigation to clearly define these conditions, but 
in the present setting it is not practical to rely on it.56 
 
 
Review of Literature 
39 | P a g e
4.4. f. Evaluation and management of AUB  
 4.4. f. i. Management of AUB in Adolescent age group 
In adolescents AUB is due to the immaturity of hypothalamo pituitary ovarian 
axis. In the first few years after menarche FS, LH, estrogen and progesterone are all 
below the adult levels. They will have anovulatory cycles that will be manifested as 
irregular cycles. Bleeding disorders like Von Willebrand disease or thrombocytopenia or 
even leukemias can manifest as menorrhagia or irregular bleed at menarche. These may 
constitute upto 20% of adolescent AUB.  
A structured history regarding recent weight loss, eating and exercise habits and 
stress factors should be elicited. History of gum bleeding or a family history of bleeding 
disorder can suggest that the AUB is due to any of the generalized bleeding disorders. 
Examination should include B.M.I, features of virulization like hirsutism, acne, 
acanthosis nigrecans, petechiae, bruises and thyroid enlargement should be looked for. 
Local causes like foreign bodies, tumors like sarcoma botryoides or case of carcinoma 
vagina should be ruled out. 
Investigation should include complete blood count, platelet, hemoglobin, and Von 
Willibrand panel including Vwf antigen assay, Factor VIII level and ristocetin cofactor 
assay. Thyroid function tests, pregnancy tests or imaging should be done as required. 
Treatment  
This depends on the degree of anemia and the amount of blood loss.  
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If there is no profound anemia or profuse blood loss then it can be treated by a 
combination of anti-fibrinolytic and anti-prostaglandin agents. 
If bleeding is profuse and has produced severe anaemia, hormonal therapy is 
required. Adolescents have deficient endometrium therefore progesterone alone to treat 
the anovulatory cycle is not sufficient. 
a) In cases where bleeding is very heavy they can be started on combined oral 
pills, four times daily and then tapered to once daily in a span of two-three 
weeks. It is followed by single daily dose, given cyclically for three to six 
months.  
b) If hemaglobin is less than 8 gm/ dL, anemia should be corrected by blood 
transfusion.57 
c) In acute heavy bleed, high dose estrogen may be required - conjugated equine 
Estrogen (25 mg) fourth hourly is given until bleeding is stopped.58 Estrogen 
acts at the capillary level.. After bleeding stops treatment can be continued as a 
21 day course of combined oral pills and then stopped to give room for 
withdrawal bleed. But if the girl is anemic, a continued course without 
interruption for a period of 2-3 months will help in correcting the anaemia.  
d) If bleeding is not profuse, conjugated equine estrogen at a lower dose of 1.25 
mg fourth hourly is started and as bleeding stops it is tapered to single daily 
dosing for 7-10 days. After 10 days progestagens like medroxy progesterone 
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acetate 10 mg daily for next 10 days is given and then both together are 
withdrawn. This is followed by cyclical combined oral pill therapy. 
 a) Von Willebrand disease 
Von Willebrand protein is a plasma protein which forms a complex with factor eight 
and prevents its proteolysis. It acts as a bridge between the damaged endothelium and the 
platelets. There are three types. Type 1 and 3 due to a quantitative defect and type 2 
caused by qualitative defect. Desmopressin is the drug of choice in severe bleeding. If not 
controlled by desmopressin Vwf concentrate has to be administered. 
b) Thrombocytopenia  
This can be due to immune or non immune causes or as a part of bone marrow failure. 
Here correction of thrombocytopenia is required. 
c) Thrombasthenia 
If other tests are inconclusive tests for platelet functions should be carried out. Platelet 
function defects like glanzmanns disease and Bernard - Soulier disease can present as 
heavy menstrual bleed.  
d) Other abnormalities of hemostasis 
Dysfibrinogenemia, prothrombin deficiency, carriers of hemophilia who have 
decreased levels of factor VIII or IX, or deficiency of other clotting factors can present as 
menorrhagia. Treatment will include fresh frozen plasma or cryoprecipitate. 
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Adolescents with Polycystic ovarian syndrome can have oligomennorhoea or at 
times amenorrhoea followed by excessive bleed. Therefore cycles should be regularized. 
Medroxyprogesterone acetate can be given from day 1 to 10. In case any of the imaging 
studies demonstrate endometrial calcification in a patient with AUB, genital tuberculosis 
should be ruled out.57 
4. 4. f. ii. Management of AUB in child bearing age group 
When patients in this age group present, a detailed history including menstrual 
history, past history, family history and drug history is taken.  A sudden change from 
normal to irregular menses may be pointing towards the diagnosis of pregnancy. Acute 
onset heavy menstrual bleed may be due to acquired defect in coagulation or points to a 
diagnosis of blood dyscracias. History of regular cycles with intermenstrual bleed 
suggests a fibroid polyp, submucus myoma or a premalignant or malignant lesion. The 
pattern of bleed in an anovulatory cycle is usually irregular without a definite pattern 
manifested as prolonged spotting per vagina or heavy menstrual bleeding without any 
pain. Ovulatory cycles have regular menses with mittelschmerz and premenstrual 
symptoms. History of passing clots rules out any coagulation defect.  
A complete examination of the patient is done. The general condition assessed. 
History of gum bleed and easy bruisability is taken. Investigations should include a 
complete blood count including platelet and a peripheral smear. Thyroid function should 
be evaluated. ACOG bulletin recommends Von Willebrand panel assay in all patients 
with menorrhagia prior to hysterectomy. The endometrium of the patient is assessed by a 
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routine transvaginal ultrasound to see for any contributory anatomical lesions and any 
chance of malignancy should be ruled out (91-96% sensitivity). A thick endometrial 
shadow in a transvaginal scan can be a hyperplastic endometrium or a polyp. These are 
differentiated using a saline infusion hysterosonography (SIS). The third and the most 
accurate diagnostic tool is a hysteroscope. They can accurately differentiate between an 
anatomical lesion and a frank malignancy. An operative hysteroscopy allows a resection 
at the same sitting or a directed biopsy is taken. Alternatively endometrial sampling can 
be taken in the office setting using a PIPELLE aspirator or can be obtained by a 
conventional curettage that can be both diagnostic and therapeutic.57 
Table-3: Types of endometrial hyperplasia with chances of malignancy59
Types of endometrial hyperplasia Percentage (%) 
Simple hyperplasia without atypia 1% 
Simple hyperplasia with atypia 8% 
Complex hyperplasia without atypia 3% 
Complex hyperplasia with atypia. 29% 
    
As per Fraser and Sengurtekein, excessive bleeding of uterine origin that is not 
due to a pelvic pathology or due to complications of pregnancy or any systemic disease is 
termed as dysfunctional uterine bleed. This can be both ovulatory and anovulatory.60 
Management of anovulatory DUB in reproductive age group
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It depends on the severity of the condition and the need for contraception. Patients 
should be counseled that irregular treatment can lead to even more erratic bleeding. 
A) Progestagens: As the fundamental problem is an unopposed estrogen action and 
progesterone deficiency, progestagens can induce a medial curettage. 19-nor testosterone 
derivative, that is norethisterone is best for hemostasis. It can be started as 5 mg thrice 
daily, if bleeding persists escalate to 10mg thrice daily, it can be continued for as long as 
15 days and then withdrawn. The next cycle should start with safer progesterone like 
medroxyprogesterone acetae. Treatment is continued for three such cycles. In case of an 
endometrial sampling report of complex hyperplasia, long term progestagens for nine 
months should be given. 
B) In women desiring contraception combined estrogen progesterone pills and even 
transdermal patches can be used. Women desiring children can be treated with ovulation 
induction agent. 
C) Levonorgestrel IUCD  
This system delivers a 20 mcg of levonorgestrel to the uterus daily. Its effects are 
superior to oral contraceptive devices. 86% women experience a reduction in amount of 
flow within 3 months. Fertility is reversible with this treatment.57 
Management of ovulatory DUB in reproductive age group 
Here anti-fibrinolytic agents have a role. Patient can be treated with acombination 
of tranexamic acid and mefenamic acid. Combined oral pills can be used or a more 
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effective treatment would be the use of a Levonorgestrel IUCD. Other medical methods 
include Danazol which causes a suppression of gonadotropins, thereby ovulation and then 
inducing hypo or amenorrhoea. GnRH analogues as well as antagonists given in monthly 
high doses will suppress the pituitary.57 
Minimally invasive surgeries for DUB 
Endometrium is destroyed by means for different energy sources. Endometrial 
ablation has shown 90% reduction in bleeding and can cause even amennoerhoea.  
They are of two types 
A) First generation endometrial abalation: Resectoscopic endometrial ablation.  
B) Second generation endometrial abalation: Non resectoscopic endometrial  
                ablation. 
A) First generation endometrial abalation   
Resectoscopic endometrial ablation-it involves the use of the operative 
hysteroscope with the resectoscope. It was started in 1980s with basic concept borrowed 
from transurethral resection of prostate. Women with ovulatory DUB are the best 
candidates for this procedure. For those with AUB and bleeding disorders it serves as an 
adjuvant treatment. The rate of post procedure amenorrrhoea is 35%.Women having 
anovulatory bleeding benefit better with medical therapy with progestagens. Women with 
polycystic ovaries are not good candidates for endometrial ablation as there are chances 
for missing premalignant lesions of endometrium. Diagnostic hysteroscopy with 
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endometrial sampling is a must before this procedure. Women with submucous fibroids 
and polyp can also be treated by hysteroscopic resection. 
Procedure 
Distension media used are non-electrolyte distension media like sorbitol, glycine, 
dextran or mannitol. For the power source either eletrocautery or laser is used. The main 
instrument is a hysteroscope with a resectoscope. 
The uterine cavity is distended with any of the above solutions. Then, with a wire 
loop electrode small strips of endometrium 7 mm wide and 4 mm deep are shaved off. 
This procedure is called Trans-cervical resection of endometrium (TCRE). There is a 
separate channel for the outflow of fluid and debris.61  
Image-5: Trans-cervical resection of endometrium (TCRE) 
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Laser Ablation 
Nd Yag laser is used for ablation of endometrium upto a depth of 6mm. Gold 
Rath. et. al. developed this technique in 1979. Success rates are about 83%, but the 
procedure is difficult to learn and is costly. 
Roller ball ablation of endometrium 
Ball electrode of 3mm connected to a monopolar coagulation system is used here. 
Roller ball is best for ablating the cornual regions. In presence of polyps and fibroids a 
combined procedure of resection and ablation is preferred. Pre-operative preparation with 
danazol helps in thinning the endometrium. This pre-operative preparation of 
endometrium showed higher rates of post-procedure amenorrhoea and lower rates of 
dysmenorrhoea along with shorter surgical time (Cochrane review). 
Complications of endometrial ablation  
1. Distension media related complications: This is commonly seen with non-
electrolyte distension media as most of the solutions are hypo osmolar. If they get 
absorbed into the system it can cause dilutional hyponatremia, hypo osmolality 
and brain oedema. Premenopausal women, due to the inhibitory effect of oestogen 
and progesterone on the sodium pump are at a higher risk for brain oedema. The 
recent use of bipolar cautery facilitates the use of electrolyte medium like normal 
saline. There are automated systems available that help in measuring the fluid 
deficit in the system giving a clue about the intravasated fluid. 
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2. Injury to viscera through a perforation in the uterus. 
3. Long term complications like hematometra and pelvic pain. 
4. Missing a diagnosis of endometrial carcinoma. 
30-40% of patients required a repeat procedure within 4 years. 
B) Second generation 
Non Resectoscopic Endometrial Ablation (NREA) without using a resectoscope, 
devices are kept inside the endometrial cavity and endometrium destroyed using different 
energy sources. These techniques have fewer complications; require shorter time and less 
training. 
a) Thermal balloon ablation: A balloon is placed in the endometrial cavity and is 
distended using a pre-heated fluid. Two types of such devices. 
i. Therma choice system  
ii. Caveterm thermal balloon  
i. Therma choice system; 
System consists of a disposable balloon catheter of 5.5 mm with a heating 
element inside. The pressure and temperature are set in the controller unit. The 
balloon is distended with 5% dextrose. The temperature is maintained at 870 C at 
160-180 mmHg and treatment is given for 8 minutes. Complications like 
electrolyte imbalance and perforation are not present. 
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ii. Caveterm thermal balloon  
The System consists of a flexible silicone balloon which approximate 
better with the endometrium. Glycine is pumped into the balloon at 750 C for a 
period of about 15 minutes. 
Image-6: Caveterm thermal balloon 
 
b) Microwave endometrial ablation: Endometrium is ablated using microwave 
 energy at 9.2 GHz at 42 W. A depth of 5-6 mm can be obtained. Amenorrhoea 
 rate is 53% and satisfaction rates are 87%. An important complication is 
perforation of uterus.  
c) Cryotherapy Endometrium is destroyed by freezing to -900 C. A freeze zone of  
1.5mm is obtained in 10 minutes. 
d) Endometrial laser intrauterine thermo therapy (ELIT) :This device developed 
by Donez and Johns, consists of multiple laser fibers. Nd YAG laser or diode 
laser is used to obtain a depth of 6 mm in 5 minutes.  
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e) Radiofrequency endometrial ablation: The 1 year satisfaction rate with this 
technique was as high as 92.8%. No pre-operative thinning of uterine cavity is 
required. It can be done under local anesthesia. Here, radiofrequency energy is 
used for automated endometrial ablation. A 7.2 mm probe is used to deliver a 
bipolar current for 80-90 seconds. The depth of tissue is controlled automatically. 
The device available in market is Novasure. 
f)Thermal destruction with preheated fluid:  It is used in situations where the uterine 
pressure of < 40 cm of water for a period of 3 minutes, via a narrow disposable 
sheet of 3mm under hysteroscopic guidance. 
g) Photo dynamic therapy: Endometrium is ablated by light of a particular wave-
length with a photo sensitizer like 5-amino levulinic acid.57 
Comparison of oral medical therapy, Levo norgestrol IUCD, EA and Hysterectomy 
Only a minority of women were compliant with long term oral therapy. For 
women who refused medical treatment, who do not require fertility preservation, EA is 
an option. If fertility preservation is required levonorgestrol IUCD is preferred. The 
ablative procedures need theatre settings whereas IUCD insertion is an office procedure. 
The satisfaction rates were as high as 95% with hysterectomy compared to endometrial 
ablation. Therefore, hysterectomy was done in women who do not respond to 
conservative treatment and in those who had recurrence following minimally invasive 
surgeries.62 
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4.4. f. iii. Evaluation of AUB in perimenopausal age group 
  Here the most important aspect in the management of AUB is to rule out 
malignancy. 
Patients developing AUB in this age group are thoroughly examined. Systemic 
and endocrine abnormalities are ruled out. Abdominal masses are looked out for. A 
complete gynecological examination is mandatory. A cervical smear including an 
endocervical smear with a brush is compulsory. The next important investigation is 
transvaginal ultrasound (TVUS) with careful evaluation of endometrium, myometrium, 
endocervix and adenxa. Focal and diffuse lesions are delineated by saline infusion 
sonography and finally a hystereoscopy.57  
Endometrial sampling is mandatory in any woman with AUB in menopausal and 
perimenopausal age group. An endometrial thickness <4mm (9mm in tamoxifen users), 
absence of any irregularity and a normal sub endometrial halo is considered normal and 
sampling can be withheld. But if repeat bleeding occurs sampling must be done. For 
sampling, studies show that Pipelle aspirator is much superior to regular curettage and 
vacuum aspirator with a specimen adequacy of 84.1% for Pipelle than the lesser 45% for 
curettage with chances of missing focal lesions.63 Hysteroscopy is the best way to 
diagnose benign as well as malignant focal lesions and a guided biopsy is most ideal. 
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Image-7: Pipelle aspirator  
 
In case of polys and local lesions a hysteroscopic resection can be done in the 
same sitting. If histopathology reveals atypical hyperplasia hysterectomy is the treatment 
of choice. If malignancy is detected it must be treated accordingly. If no cause is found 
out bleeding may be anovulatory. Women with proliferative endometrium without atypia 
are treated with medroxyprogesterone acetate (10mg daily for 10 days a month or it can 
be given cyclically).  Another option is the insertion of an LNG-IUCD. In women taking 
HRT (Hormone Replacement Therapy), irregular bleeding can be tackled by increasing 
the dose of progesterone. But if bleeding continues for more than 3-4 months, patients 
requires re-evaluation.57 
4.5. Thyroid disease and female reproduction 
4.5. a. Hypothyroidism  
Hypothyroidism in women in the reproductive (20-40 years) is usually caused by 
Autoimmune Thyroid Disease (AITD). Hypothyroidism is associated with manifestations 
like abnormal sexual development, menstrual irregularities and infertility. The 
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association between hypothyroidism and abnormal menstrual patterns were recognized 
way back  in the  1950s and   changes in cycle length and blood flow were identified .The 
higher the serum TSH level  more severe were the menstrual abnormalities. Severe 
hypothyroidism is associated with ovulatory dysfunction .This is caused by an associated 
hyperprolatcinaemia, caused by an increase in TRH production, and an alteration in 
GnRH pulsatile secretion. This leads to a delay in LH response and an inadequate corpus 
luteum. 
The response of the ovaries to thyroid hormone could be explained by the 
presence of thyroid hormone receptors in human o tes. The synergistic action of 
thyroid hormones on the FSH-mediated LH/HCG - receptor, helps to exerts a stimulatory 
effect on granulosa cell (for progesterone production).  Hypothyroidism also causes an 
alteration in the peripheral metabolism of oestrogen and also decreases SHBG 
production. These mechanisms lead to an abnormal feedback effect at the pituitary level. 
Hypothyroidism can also alter the production of coagulation factors (decreased levels of 
factors VII, VIII, IX and XI) leading to menorrhagia. 
4.5. b. Subclinical and overt hyperthyroidism 
In hyperthyroid women, the production of SHBG is increased; the metabolism of 
estrogen altered, and there is an increased conversion of androgens to estrogen. Increased 
thyroid hormone levels, cause an increase in the gonadotropin response to GnRH and the 
baseline concentrations of gonadotropin is also elevated. The effect on hemostatic 
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factors, including the synthesis of factor VIII, explains the decreased menstrual flow.  
Treatment of hyperthyroidism frequently corrects the cycle changes. 
4.5. c. Autoimmune thyroid disesase (AITD) 
AITD is 5-10 times more prevalent in women than in men which may be due to 
various genetic factors, effects of estrogen and abnormalities in X chromosome.  AITD is 
one of the commonest autoimmune disorders in women, affecting 5-10% of women in 
reproductive age group and also the most frequent cause of thyroid dysfunction. 
Adequate levels of thyroid hormones are quintessential in the normal 
steroidogenesis by ovary. T3 modulates the effect of gonadotropins, FSH and LH on 
normal steroid biosynthesis. Studies have identified T3 binding sites within human 
oocytes. Thyroid hormones potentiate the action of estrogen and enhance estrogenic 
responses, like prolactin production in the pituitary. This demonstrates the important role 
of thyroid hormones in normal reproductive function ; through their direct effects on the 
ovary and also  indirectly by interacting with sex hormone binding globulins. Thus, 
abnormalities in thyroid hormone function can lead to reversible menstrual irregularities 
and infertility.64, 65 
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4.6. Endocrinology of thyroid gland 
 4.6. a. Historical perspective 
   First named by the anatomist THOMAS WHARTON in 1658 
(meaning oblong shield), as the shape resembled the shields used in Ancient Greece. It 
was believed that the function of the thyroid was to fill vacant spaces and contribute to 
the shape and beauty of neck, especially in woman.5     
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Image-8-: Anatomy of the Thyroid gland  
 
4.6. b. Chemistry of thyroid hormones 
Iodination of amino acid tyrosine leads to formation of T3 and T 4. One or more 
atoms added to tyrosine molecule; monoiodotyrosine (MIT) and diiodotyrosine (DIT) .66 
   DIT + DIT    T 4   and   MIT +DIT   T 3 
4.6. c. Steps in synthesis of thyroid hormones  
i)  Iodine trapping:  
  Inorganic iodide gets absorbed and circulates in the blood (about 150 mcg) and is 
cleared by the thyroid. The thyroid to serum ratio of iodide is around 25:1 which rises to  
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250:1 in thyroid deficiency. Perchlorate and thiocyanate can block iodide pumps by 
competing with iodide for their carrier mechanism. 
ii) Oxidation of iodide: The oxidation of iodide occurs at the cell colloid interface, in the 
microvilli with the help of membrane bound peroxidases. This process can be blocked by 
propylthiouracil and carbimazole. 
Image-9: Iodine trapping and oxidation 
 
iii) Synthesis of thyroiglobulin: Thyroglobulin is synthesized in ribosomes and are then 
stored in vesicles. They are then extruded by exocytosis. 
iv) Thyroid molecules attach to thyroglobulin molecules by peptide linkages within the 
lumen. Iodine then attaches to tyrosyl groups. 
Review of Literature 
58 | P a g e
Image-10: Iodination of tyrosine and coupling 
v) Coupling of iodotyrosines to form T3 and T 4 .MIT and DIT then undergo coupling 
to form triiodo and tetraiodo tyrosines, which  remain attached to the thyroglobulin and 
forms the storage depot. 
vi) Release of T3 and T4: Colloid is ingested by pinocytosis; then it undergoes proteolysis 
in lysosomes and releases T3 and   T 4.in ratio of 20-30:1.67,68 
99.5% of thyroid hormone is protein bound. T4 10 times more than T3.75% of 
both hormones are bound to (TBG) thyroxine binding globulin; 15% of T4 alone to 
thyroxine binding prealbumin and10 percent of T4 and 25 percent  of T3 is bound to 
albumin. Free T3 and T 4 are de-iodinated in cells all over the body.T4 is converted toT3 
and free iodide which are excreted in the urine (20% in bile).A part of the T4 is converted 
to the inactive isomer called reverse T3.its levels increase in starvation, illness and after 
major surgery and in fetus from the conversion of the maternal T4.36 
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The structure of Thyroxine was determined by Harrington and Barger in 1927, 
Tridothyronine by Gross, PittRivers and Roche et al in 1952.
4.6. d. Regulation of thyroid hormone  
  Neuroendocrine  hypothalamic pituitary  thyroid peripheral tissue axis regulates 
the thyroid hormone. Production of T3 and T4 in the thyroid gland is stimulated by the 
TSH (thyrotrophin, thyroid stimulating hormone) released from the thyrotrophs of 
anterior pituitary in response to hypothalamic TRH (thyrotrophin releasing hormone) 
.There is a negative feedback of thyroid hormones on the thyrotrophs such that when 
plasma concentrations of T3 and T4 are raised, TSH secretion is suppressed whereas 
cases with low T3 and T4 circulating TSH levels are high.69 
Image-11: Hypothalamo Pituitary thyroid axis  
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4.6. e. Mechanism of action of thyroid hormones  
Thyroid hormone receptors belong to a large family of nuclear receptors which 
include receptors for steroid hormones. The receptors function as hormone-activated 
transcription factors and modulate gene expression. Unlike steroid hormone receptors, 
thyroid hormone receptors bind DNA even in the absence of hormone, leading to 
transcriptional repression. Binding of hormone brings about a conformational change in 
the receptor, helping it to act a transcriptional factor. 
Variation in expression of the different forms of thyroid hormone receptors in 
different tissues, in different stages of development  
There are four different types of thyroid hormone receptors: alpha-1, alpha-2, 
beta-1 and beta-2.Of these alpha-1, alpha-2 and beta-1 isoforms are expressed in almost 
all tissues, whereas beta-2 is synthesized exclusively in hypothalamus, anterior pituitary 
and developing ear. The first receptor to be expressed in intrauterine life is 1 and beta 
receptors are increasingly expressed in the brain soon after birth. Beta receptors 
preferentially activates expression of genes important in brain development (e.g. myelin 
basic protein), and therefore upregulation of this particular receptor is crucial to 
the effects of thyroid hormones in the development of the fetal and neonatal brain. Thus, 
the presence of multiple forms of thyroid hormone receptors, with tissue and 
developmental stage-dependent difference in expression, suggests a high level of 
complexity in the physiologic effects of thyroid hormone.70 
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4.6. f. Physiological functions of thyroid hormones  
a) Carbohydrate Metabolism: Increase the rate of hepatic glucose production, 
principally by increasing hepatic gluconeogenic activity. 
b) Protein Metabolism: Stimulate the proteolysis mainly muscle.
c) Lipid Metabolism: Thyroid hormones increase lipolysis and also enhance 
lipogenesis 
d) Na-K Pump Activity: Increases in the activity of the Na-K pump in the plasma 
membrane. 
e) Thermogenesis: Increase the body temperature.  
f) Effect on BMR: Increase the body BMR. 
g) Growth and development: Normal human development.71  
4.6. g. Thyroid during pregnancy 
During pregnancy, the increasing levels of estrogen cause the TBG to increase 
upto three times. In most antenatal subjects, thyroid hormones levels remain fairly 
constant; whereas in some, the levels decrease by 10% approximately, though these 
individuals usually maintain euthyroid status. The resulting increase in thyroid hormone 
production, combined with increased levels of thyroid hormone metabolism (consequent 
loss of iodine in urine) and with fetal iodine uptake for its own thyroid hormone synthesis 
means that maternal iodine requirement increases slightly during pregnancy.72  
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4. 6.h. Thyroid Function Test 
  Determination of circulating levels of thyroid hormones is essential for an 
accurate assessment of the functional status of thyroid in patients. Serum thyroxine (T4) 
concentration was the most useful first line test for many years. Serum T4 is determined 
almost exclusively by RIA, values in euthyroid patients ranges 5-12 µg/dl. In general 
(except T3 thyrotoxicosis etc.,) the value of T3 (serum triodothyronine) is parallel with 
T4 level and ranges in healthy subjects from 80-200 ng/dl. Reverse T3 (rT3) varies from 
10-60 ng/dl. T3 values are often elevated in non-thyroidal illness. To assess the patients 
true metabolic status estimation of the concentration of free T4 or free T3  the active 
hormones is advisable by equilibrium dialysis, which is the most precise method, 
although not available in all the centers. 
Serum thyrotropin (thyroid stimulating hormone, TSH) has been a reliable 
indicator of primary hypothyroidism with levels rising even when thyroid deficiency is 
mild and T4 level still normal. Although RIAs were developed that could detect TSH 
concentrations in the range of 0.1-0.3 µg/ml, it was achieved only by extensive 
purification. Commercially available RIAs have not provided quantitative value s below 
1 µU/ml. Second generation assays detect TSH in the range of 0.1 to 0.5 µU/ml and third 
generation assay have a 10 fold greater functional sensitivity.   
Fourth generation assays are extremely sensitive and can detect TSH levels = 
0.004 mU/l, but for practical purposes assay. Sensitive to = 0.1 mU/l are sufficient. The 
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widespread availability of TSH IRMA has made the TRH stimulation test virtually 
obsolute.73 
4.6. i. Types of thyroid disorders  
Specific kinds of thyroid disorders exist that include  
Hypothyroidism 
Hyperthyroidism 
Goiter 
Thyroid nodules 
Thyroid cancer 
4.6. i. i. Hypothyroidism  
It is caused due to the thyroid gland producing an insufficient amount of thyroid 
hormone. It can be due to problems within the thyroid gland, pituitary gland or 
hypothalamus.  
Symptoms include: Fatigue, poor concentration or feeling mentally "foggy", 
constipation, feeling cold, fluid retention, muscle and joint aches, depression, prolonged 
or excessive menstrual bleeding in women. 
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Management of hypothyroidism  
Levothyroxine (Synthetic Thyroxine / T4) 
Liothyronine (Synthetic Triiodothyronine / T3) 
Liotrix is a synthetic combination of thyroxine and triiodothyronine (T4 and 
T3). 
 
4.6. i. ii. Hyperthyroidism  
It is caused due to excessive production of thyroid hormone. It is less common 
condition than hypothyroidism. Symptoms relate to increased metabolism in cases of 
hyperthyroidism. Apparent symptoms may not be present in mild cases.  
Symptoms and signs: Tremor, nervousness, increased heart rate, fatigue, intolerance for 
heat, increase in bowel movements, increased sweating, concentration problems and 
unintentional weight loss. 
Management of hyperthyroidism  
Classification of Anti-thyroid drugs  
Class-I: Inhibit Hormone synthesis (Anti-thyroid drugs): Propylthiouracil, 
Methimazole, Carbimazole. 
Class-II: Inhibit iodide trapping: Thio-cyanates, Perchlorates, Nitrates. 
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Class-III: Inhibit hormone release: Iodine, Sodium Iodide, Potassium Iodide, Organic 
Iodide. 
Class-IV:  Destroy thyroid tissue: 131I, 125I and 123I.74, 75 
Thyroidectomy: Subtotal thyroidectomy is the oldest form of treatment for 
hyperthyroidism. Others include total thyroidectomy, combinations of 
hemithyroidectomies, contralateral & subtotal thyroidectomies. 
4.6. j. Diagnosis of thyroid disorders  
General Survey  
1. Build and nutrition  Patients suffering from thyrotoxicosis are usually thin and 
underweight. They have excessive sweating, moist skin & muscle wasting. In 
hypothyroidism reverse is true (dry skin, obese).  
2. Facies  In patients suffering from thyrotoxicosis there is a facial expression of 
excitement, tension, nervousness with or without variable degree of exopthalmus. 
Mask like puffy face is seen in hypothyroidism.  
3. Mental State and intelligence - Hypothyroid patients are dull with low intelligence 
level.  
4. Pulse rate - Sleeping pulse rate is very useful index to determine the degree of 
thyrotoxicosis.         
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5. Eye signs should be looked for in primary thyrotoxicosis. 
Lid retraction: Upper eye lid is higher than normal 
Exopthalmos: Eyeball is pushed forwards due to increase in fat / odema / cellular 
infiltration in the retroorbital space  
Eyelids are retracted: Weakness of ocular muscles (Opthalmoplegia) by examining 
eye movements.  
Chemosis (oedema) of conjunctiva are eye signs to be looked for. 
6. Thyroid is examined for any enlargement, nodules cyst or any features suggestive of  
    Malignancy. 
7. Blood test: To measure levels of thyroid hormones T3, T4, TSH. Other tests may   
include Antibodies against thyroid tissue e.g. anti-thyroglobulin, anti-thyroperoxidase or 
TSH receptor stimulating antibodies. 
8. Ultrasound: Helps in visualization of the consistency of the tissue within the gland.   
Cysts / calcifications / increased vascularity may be revealed.  
9. Thyroid scans using radioactive iodine: Intravenous administration of radioactively 
labeled iodine results in uptake by the thyroid gland which is visualized by imaging test. 
Areas or nodules producing excess hormone (hyperfunctioning) shows an increased 
uptake of iodine. 
10. Fine needle aspiration and biopsy: include techniques that remove a sample of cells 
or tissue from the thyroid gland for examination and diagnosis by a pathologist.76  
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5. Materials and Methods  
5.1. Study design:  It is a cross sectional study.  
5.2. Study setting: The study was conducted in Department of Obstetrics and 
Gynecology in Sree Mookambika Institute of Medical Sciences Hospital, Kulasekharam.
5.3. Duration of stud: Study was conducted in the period of 2013-2014 year. 
5.4. Sample size calculation  
Sample size is selected by Epi info software. Power 80, confidence interval 95%, 
prevalence of control 1% and case are 23.4% and the calculated sample was 30 in cases 
and 30 in control.  
Formula for sample size= 4pq/d2
Where  
 P= The prevalence   
q= (100-p)   
d=allowed error (5-20% of p) 
5.5. Study groups  
Group-I:  (Control) – Randomly selected patients in the age group of 15-45.Patients 
without any menstrual complaints. (Every first patient presenting to the Gynecology 
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O.P.D. on the Mondays of first three weeks in a month with complains other than 
menstrual abnormalities will be selected) 
Group-II: (Cases) - Patients with abnormal uterine bleeding (Any case presenting to the 
Gynecology O.P.D. with complains of menstrual abnormalities in the same age group) 
5.6. Inclusion criteria 
Women between 15-45 years of age, 
Patients presenting with abnormal uterine bleeding.
5.7. Exclusion criteria 
Patients with thyroid tumor.  
Women on anti-thyroid medication. 
Patients with recent thyroid surgeries. 
Endometrial, uterine and any other reproductive organ cancers. 
Organic lesions of genital tract. 
Bleeding disorders. 
IUCD users.  
Pregnancy complication.77
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5.8. Observation  
5.8. a. Demographic data  
Case and control group’s patient’s demographic data (age, occupation, Material 
status, socioeconomic status) was collected by interview. Past and family history also 
collected from all the study population.  
5.8. b. Chief complaints  
Patients came to the OPD Gynecology department was asked for the chief 
compliments (bleeding per vagina) and other any complaints recorded in the case sheet.  
5.8. c. Gynecological history  
All the patients menstrual history, details previous menstrual cycle, obstetric history was 
collected.   
5.8. d. Clinical examination 
All the patients were subjected for general and clinical examination. Blood 
pressure, pulse rate, systemic examination and gynecological examination including per 
abdomen, vulvo vaginal examination (Healthy/Non Healthy), per speculum examination 
and bimanual Vaginal Examination. Ultrasound was also performed in all the patients.78 
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5.8.e. Biochemical investigations 
 From controls and cases 2 ml of blood was collected and used to measure Hb (Sahli 
Method), platelet count (Auto mated platelet counter), Bleeding time (Duke Method), 
clotting time (Capillary tube method). Serum was separated and used for the estimation 
of thyroid hormones by ELISA method. 
5. 8. f. Thyroid hormone (T3, T4, &TSH) estimation by ELISA method 
5.8. f. i. Specimen collection and preparation: Serum prepared from a whole blood 
specimen obtained by acceptable medical techniques. Serum sample stored at 48 hours at 
2-8°C prior to assaying.  
5.8. f. ii. Instruments and materials: A micro titer well reader with a bandwidth of 
10nm or less and an optical density range of 0 to 2 OD or greater at 450 nm wavelength 
is acceptable for absorbance measurement. Distilled water, micropipettes (0.5, 1, 2 and 5 
ml), pipette tips, absorbent materials and ELISA reader are required 
5.8. f. iii. Assay Procedure 
1. Secure the desired number of coated wells in the holder 
2. Dispense 100 µl of standards, specimens, and controls (not included in kit) into 
appropriate wells.  
3. Dispense 100 µl of Enzyme Conjugate Reagent into each well. 
4. Thoroughly mix for 30 seconds. It is very important to have completed mixing. 
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5. Incubate at room temperature (18-25°C) with shaking at 175±25 RPM for 120 minutes 
(2 hours). 
6. Remove the incubation mixture by flicking plate contents into a waste container. 
7. Rinse and flick the microtiter wells 5 times with distilled or dionized water. (Please do 
not use tap water.) 
8. Strike the wells sharply onto absorbent paper or paper towels to remove all residual 
water droplets. 
9. Dispense 100 µl of TMB Reagent into each well. Gently mix for 5 seconds. 
10. Incubate at room temperature, for 20 minutes. 
11. Stop the reaction by adding 100 µl of Stop Solution into each well. 
12. Gently mix for 30 seconds. Ensure that all of the blue color, changes completely to 
yellow. 
13. Read OD at 450 nm with a microtiter well reader within 15minutes.79
Hormone T3 T4   TSH
Normal lab values  2.15-6.45 p mol/L 10.32 -25.8 p mol/L 0.39 -6.16 p mol/L 
5.8.12. Statistical analysis  
The data was analyzed by SPSS (16.0) version. Chi-square and t- test was applied to find 
the statistical significance at 95% confidence interval between group-I and II. The p value 
less than 0.05 will be considered statistically significant. Data was expressed in number, 
percentage and MEAN±SEM.80

Results
72 | P a g e
6. Results
6.1. Assessment of demographic data
Table-4: Distribution of number of patients according to age in cases and controls groups
Age (years) Group-I (Control) Group-II (Cases)
<20 years 00 02
21-30 years 07 05
31-40 years 14 10
41-45 years 09 13
Graph-12: Distribution of percentage of patients according to age in cases and controls
groups
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Table-4: According to the above table maximum number of patients presenting with AUB were
in the age group of 41-45 years that is 43.3% and 33.3% were in the age group of 31-40 years
and the least were in the age group <20 years. But the majority of patients attending the OPD for
Complaints other than abnormal uterine bleeding were between 31-40 years.
Table-5: Distribution of number of patients according to occupation in cases and controls
groups
Occupation Group-I (Control) Group-II (Cases)
House wife 18 18
Employee 09 05
Student 01 04
Unskilled labor 02 03
Graph-13: Distribution of percentage of patients according to occupation in controls and
cases groups
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Table-5: In both controls and cases maximum numbers of patients were house wives. Only 4
patients were students among cases and only one student was present in the control group.
Table-6: Distribution of number of patients according to marital status in cases and
controls groups
Marital status Group-I (Control) Group-II (Cases)
Married 29 26
Unmarried 1 4
Graph-14: Distribution of percentage of patients according to marital status in cases and
controls groups
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Table-6: Among both controls and cases majority of patients were married.13.3% of women
among patients presenting with abnormal uterine bleeding were unmarried as compared to only
3% in the control group
Table-7: Distribution of number of patients according to socio-economic status in cases and
controls groups
Socio-economic status Group-I (Control) Group-II (Cases)
Upper middle class 20 17
Lower middle class 10 13
Graph-15: Distribution of percentage of patients according to socio-economic status in
controls
Results
76 | P a g e
Graph-16: Distribution of percentage of patients according to socio-economic status in
cases
Table-7: Both controls and cases had more number of people in upper middle class than lower
middle class. There was lesser number of patients from upper middle class families among cases
compared to controls. But the numbers of patients from lower middle class were more among
cases than controls.
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Table-8: Distribution of number of patients according to nutritional status in cases and
controls groups
Nutritional status Group-I (Control) Group-II (Cases)
Poor 00 01
Moderate 30 29
Table-8: In the control group all the patients were moderately built and nourished. Among cases
only one patient was poorly built and nourished.
Graph-17: Distribution of percentage of patients according to nutritional status in cases
and controls groups
Table-9: Comparison of past history between control and case groups
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Past history Group-I (Control) Group-II (Cases)
Number Percentage (%) Number Percentage (%)
No past medical
history
21 70.00 21 70.00
Hypertension 00 00.00 01 03.33
Asthma 03 10.00 02 06.67
Diabetes mellitus 01 03.33 01 03.33
PCOD 00 00.00 01 03.33
Breast lump
excision
01 03.33 00 00.00
Ovarian cyst 01 03.33 00 00.00
Suffering from
more than one
diseases
02 06.67 03 10.00
Table-9: In both groups equal number of subjects had, no relevant past history. 2 in controls and
3 in cases group had more than two diseases. There was no hypertensive, PCOD subjects in
control group. No subjects had history of breast lump or ovarian cyst among cases.
Table-10: Comparison of family history between control and case
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Family history Group-I (Control) Group-II (Cases)
Number Percentage (%) Number Percentage (%)
a) No family medical
history
23 76.67 22 73.33
b) Hypertension 03 10.00 00 00.00
c) Asthma 00 00.00 01 03.33
d) Diabetes mellitus 00 00.00 04 13.33
e) Hypothyroidism 01 03.33 00 00.00
f) Suffering from more
than one diseases
03 10.00 03 10.00
Table-10: 23 in control group and 22 in case group had no relevant family history. There was no
family history of bronchial asthma or diabetes in the control group. No family history of
hypertension and hypothyroidism in case group. Equal number of patients had family history
of more than two diseases.
6.2. Menstrual history
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Table-11: Comparison of previous menstrual history of cases and control groups
Menstrual history Group-I (Control)
(MEAN±SEM)
Group-II (Cases)
(MEAN±SEM)
P values
Age of menarche 14.00±0.22 13.90±0.21 0.786
Duration of cycle
(days)
29.57±0.31 31.83±1.43 0.567
Duration of flow
(days)
4.13±0.18 5.17±0.28* 0.02
(p < 0.05 significant when duration of flow between controls and cases was compared)
Graph-18: Comparison of mean age at menarche between controls and cases
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Graph-19: Comparison of mean duration of menstrual cycles and duration of flow between
controls and cases
Table-11: No significant difference in mean values for age at menarche, duration of cycle
between control and case groups. But duration of flow showed significant difference between
controls and cases.
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Table-12: Distribution of patients according to amount of flow in cases and controls
Amount of
flow
Group-I (Control) Group-II (Cases)
Number Percentage (%) Number Percentage (%)
Scanty 00 00.00 00 00.00
Moderate 30 100.0 30 100.0
Excessive 00 00.00 00 00.00
Table-12: No scanty and excessive flow observed in control and case groups. All the patients
had moderate flow.
The above two tables showed that no relation was found between age at menarche, previous
cycle length and flow on future progression to abnormal uterine bleeding. But there was
significant increase in the number of days of flow in cases compared to controls.
Table-13: Comparison of obstetric history between cases and controls
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Obstetric
history
Group-I Control
(MEAN±SEM)
Case (MEAN±SEM) P value
Married life 12.65±7.55 15.13±9.17 0.26
Para 0.93±0.98 1.70±0.98* 0.00
Abortion 0.33±0.71 0.07±0.25* 0.05
Last delivery 7.37±7.96 11.83±7.96* 0.03
(*P < 0.05 shows significant difference when mean values of parity, abortions and last
delivery were compared between controls and cases, P > 0.05 showed no significant
difference when mean married life was compared between controls and cases)
Table-13: The above table shows that there is significant difference in the parity, number of
abortions and last child birth between the controls and cases. But years of married life showed no
significant difference among the groups. This can be accounted for by the fact that patients
presenting with abnormal uterine bleeding were from the older age group compared to that in
the control group.
Table-14: Distribution of patients in cases and controls according to Obstetric score
Results
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Obstetric score Group-I (Control) Group-II (Cases)
Number Percentage (%) Number Percentage (%)
Nulli parous 14 46.67 6 20.00
Para 1 5 16.67 5 16.67
Para 2 10 33.33 13 43.33
Para 3 1 03.33 6 20.00
Table-14: 14 Peoples in controls and 6 in cases were nulliparous. Equal number of people had 1
child in case and control groups. 10 in control and 13 in cases had 2 children. Only 1 in control
and 6 in case group has 3 children.
Graph-20: Comparison of number tubetomized patients between controls and cases
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Table-15: Distribution of patients according to per speculum findings in controls and cases
Results
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Per speculum
examination
Group-I (Control) Group-II (Cases)
Number Percentage (%) Number Percentage (%)
Normal 19 63.33 14 46.67
Cervix
unhealthy
11 36.67 11 36.67
Abnormal
Discharge
09 30.00 05 16.67
Not done 01 3.33 04 13.33
Table-15: In 1 patient in controls and 4 patients in cases per speculum examination was not done
19 patients among controls and 11 patients among cases had normal per speculum examination.
63% of controls and 46.67% cases had healthy cervices.
Table-16: Distribution of patients according to per speculum findings in the study
population
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Per speculum
examination
Total study population
Number Percentage (%)
Normal 33 55.00
Cervix unhealthy 22 36.67
Discharge 14 23.33
Not done 5 08.33
Table-16: In 8.33% of the population speculum examination was not done. 36.67% of all the 60
patients in the study had unhealthy cervices and 23.3% had abnormal discharge P/V. These
points to the importance of complete Gynacecological examination in all patients presenting to
the department of Gynaecology.
6.3. General and systemic examination
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Table-17: Comparison of pulse rate, systolic and diastolic blood pressure between the
controls and cases
Cardiovascular
parameter
Group-I Controls
(MEAN±SEM)
Group-II Cases
(MEAN±SEM)
P value
Pulse rate 73.33±0.65 76.57±1.19* 0.02
Systolic blood
pressure
116.13±1.57 113.00±1.98 0.22
Diastolic blood
pressure
75.67±1.34 75.33±2.13 0.89
(*P<0.05 was significant when pulse rate between controls and cases were compared,
P>0.05 showed no significant difference when systolic and diastolic blood pressure between
controls and cases were compared)
Table-17: The above table compares the pulse rate and blood pressure values of both cases and
controls. Pulse rate showed significant difference between controls and cases. The systolic and
diastolic blood pressure showed insignificant difference.
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6.4. Hematological parameters
Table-18: Comparison of hematological parameters between controls and cases
Hematological
parameters
Group-I Controls
(MEAN±SEM)
Group-II Cases
(MEAN±SEM)
P value
Hemoglobin 11.86±0.22 10.39±0.47 0.01*
Platelet count 3.45±0.08 3.60±0.09 0.21
Bleeding time 1.53±0.13 1.63±0.16 0.63
Clotting time 3.90±0.18 3.77±0.20 0.63
(*P<0.05 was significant when hemoglobin level between controls and cases were
compared, P>0.05 was not significant when platelet count, bleeding time and clotting time
between controls and cases were compared)
Table-18: Only hemoglobin levels showed significant difference between the groups. No
significant differences were noted in platelet count, bleeding time and clotting time compared
between cases and control. There is a numerical difference in the values but it is not statistically
significant.
6.5. Biochemical parameters
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Table-19: Comparison of thyroid profile between controls and cases
Thyroid
profile
Group-I Control
(MEAN±SEM)
Group-II Case
(MEAN±SEM)
P value
TSH 3.13±0.27 7.26±1.99* 0.01
T3 3.90±0.11 3.95±0.32* 0.02
T4 14.73±0.46 15.20±1.13* 0.04
(*P<0.05 significant compared TSH, T3, T4control group with cases)
Table-19: Comparison of mean TSH values showed high significant difference compared
between the controls and cases the p value was 0.01. T3, T4 also showed significant difference
when controls and cases were compared. The p values were 0.02 and 0.04 which were
statistically significant.
Graph-21: Comparison of mean TSH levels between controls and cases
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Graph-22: Comparison of mean T3 levels between controls and cases
Graph-23: Comparison of mean T4 levels between controls and cases
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6.6. Correlation of menstrual patterns with demographic, hematological and biochemical
parameters
Results
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Table-20: Distribution of patients according to menstrual pattern in cases group
Menstrual patterns Group-II (Cases)
Number Percentage (%)
Menorrhagia 13 43.33
PolyMenorrhagia 7 23.33
Metrorrhagia 1 03.33
Menorrhagia with infrequent cycle 3 10.00
Menometrorrhagia 2 06.68
Polymenorrhoea 3 10.00
Oligomenorrhoea 1 03.33
Total 30 100
Table-20: The above table demonstrates the different menstrual patterns among patients with
abnormal uterine bleeding. The commonest pattern was menorrhagia accounting for a total of
43.3% followed by poly menorrhagia in 23.3% of cases. Menorrhagia with infrequent cycles,
that is acyclical bleed (anovulatory cycles) were found in 10% of cases ,so also polymenorrhoea
in another 10%. The least common patterns were metrorrhagia and oligomenorrhoea.
Table-21: Distribution of number and percentage of hypothyroidism in patients in relation
to menstrual patterns in the cases group
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S. No Menstrual patterns Hypothyroidism
Number Percentage (%)
1. Menorrhagia 4 57.13
2. PolyMenorrhagia 1 14.29
3. Metrorrhagia 1 14.29
4. Menorrhagia with infrequent cycle 1 14.29
5. Menometrorrhagia 0 00.00
6. Polymenorrhoea 0 00.00
7. Oligomenorrhoea 0 00.00
Total 7 100
Table-18: The above table demonstrates the menstrual pattern among patients suffering from
hypothyroidism. The most common menstrual pattern was menorrhagia accounting for a total of
57.13%. Each of the other patterns like polymenorrhagia, metrorrhagia and menorrhagia with
infrequent cycles was seen in 14.29%. No patient with hypothyroidism had menometrorrhagia,
polymenorrhoea, or oligomenorrhoea.
Table-22: Distribution of number and percentage of euthyroid patients in relation to
menstrual patterns in cases group
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S. No Menstrual patterns Euthyroid
Number Percentage (%)
1. Menorrhagia 8 36.36
2. PolyMenorrhagia 6 27.27
3. Metrorrhagia 0 00.00
4. Menorrhagia with infrequent cycle 2 09.09
5. Menometrorrhagia 2 09.09
6. Polymenorrhoea 3 13.65
7. Oligomenorrhoea 1 04.54
Total 22 100
Table-19: This table demonstrates the pattern of bleed in patients who are euthyroid. Among
euthyroid women too the commonest menstrual pattern was menorrhagia (36.6%).This is lesser
than that seen in hypothyroid patients where it accounted for 57.13% of cases and a 100% among
hyperthyroid patients.the next common menstrual patterns were polymenorrhagia (27.7%) and
polymenorrhoea (13.65%).
Table-23: Distribution of cases according to menstrual patterns in relation with thyroid
disorder
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Menstrual
patterns
Hypothyroidism Hyperthyroidism Euthyroid
Number % Number % Number %
Menorrhagia 4 57.13 1 100 8 36.36
PolyMenorrhagia 1 14.29 0 0 6 27.27
Metrorrhagia 1 14.29 0 0 0 00.00
Menorrhagia with
infrequent cycle
1 14.29 0 0 2 09.09
Menometrorrhagia 0 00.00 0 0 2 09.09
Polymenorrhoea 0 00.00 0 0 3 13.65
Oligomenorrhoea 0 00.00 0 0 1 04.54
Total 7 100 1 100 22 100
Table-23: The above table demonstrates the menstrual pattern among patients suffering from
hypothyroidism. The most common menstrual pattern was menorrhagia accounting for a total of
57.13%. Each of the other patterns like polymenorrhagia, metrorrhagia and menorrhagia with
infrequent cycles were seen in 14.29%. No patient with hypothyroidism had menometrorrhagia,
polymenorrhoea, or oligomenorrhoea. Among patients with abnormal uterine bleeding only one
(3%) patient had hyperthyroidism and this patient had presented with menorrhagia. This table
demonstrates the pattern of bleed in patients who are euthyroid. Among euthyroid women too,
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the commonest menstrual pattern was menorrhagia (36.6%).This is lesser than that seen in
hypothyroid patients where it accounted for 57.13% of cases and a 100% among hyperthyroid
patients.the next common menstrual patterns were polymenorrhagia (27.7%) and
polymenorrhoea (13.65%).
Table-24: Mean values of thyroid hormone profile in patients with different menstrual
pattern
S. No Menstrual patterns T3
(MEAN±SEM)
T4
(MEAN±SEM)
TSH
(MEAN±SEM)
1. Menorrhagia 5.12±0.75 13.01±2.89 9.39±3.36
2. PolyMenorrhagia 3.76±0.28* 14.28±1.39 6.64±4.42*
3. Metrorrhagia 1.90±0.00*,# 15.25±0.00* 6.73±0.00*
4. Menorrhagia with
infrequent cycle
4.29±0.54*,$ 14.97±3.04 6.68±5.58*
5. Menometrorrhagia 2.85±0.45*,#,$, 14.34±3.86$ 3.18±1.62*,#,$,
6. Polymenorrhoea 4.25±0.11*,#,$ 15.11±1.76* 2.57±0.62*,#,$,
7. Oligomenorrhoea 4.16±0.00*,$ 16.55±0.00*,#,$, 1.45±0.00*,#,$, ,
(*P<0.05 was significant when T3, T4 and TSH levels were compared between patients with
menorrhagia and others, #P<0.05 was significant when T3, T4 and TSH levels between
polymenorrhagia patients and others were compared, $P<0.05 was significant when
comparing T3, T4 and TSH levels between metrorrhagia patients and others, P<0.05 was
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significant when comparing T3, T4 and TSH levels between patients with menorrhagia and
infrequent cycle and others, P<0.05 was significant when T3, T4 and TSH levels between
polymenorrhoea patients and others were compared)
Table-24: The table above co relates the different menstrual patterns and the levels of various
components in thyroid profile. The mean T3 and TSH values are highest among patients with
menorrhagia .But the mean T4 values are highest among patients with oligomenorrhoea
Table-25: Distribution of patients according menstrual patterns and age
Age (years) < 20 years 21-30 years 31-40 years > 40 years
Menorrhagia 0 1 5 7
PolyMenorrhagia 1 2 1 3
Metrorrhagia 0 0 1 0
Menorrhagia with
infrequent cycle
2 1 0 0
Menometrorrhagia 0 0 1 1
Polymenorrhoea 0 1 2 0
Oligomenorrhoea 0 0 0 1
Total 3 5 10 12
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Table-25: Menorrhagia is the commonest menstrual pattern seen in age groups of 31-40 years
and >40 years, the older age group. The commonest menstrual pattern in the age group between
21-30 years is polymenorrhagia and in patients <20 years it was menorrhagia with infrequent
cycles .This may be due to the anovulatory cycles seen around menarche
Table-26: Distribution of patients with thyroid disorders according to age
Age (years) <20 years 21-30 years 31-40 ears 41-45
Years
Hypothyroidism 1 1 1 4
Hyperthyroidism 0 0 0 1
Euthyroid 2 4 7 9
Total 3 5 8 14
Table-26: This table shows the age distribution of patients with thyroid dysfunction.
Hypothyroidism is most common in patients >40 years, that is the perimenopausal age group.
They account for 57.14% of the hypothyroid patients. The one patient detected to have
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hperthyroidsm also comes in the same age group. The rest of the hypothyroid patients were
equally distributed among all other age groups.
Table-27: Distribution of menstrual patterns of patients according to TSH levels
Menstrual pattern Normal
(0.39-6.16)
Less than
(0.39)
Between
(6.17-26.17)
Above 26.17
Menorrhagia 8 1 2 2
PolyMenorrhagia 6 0 1
Metrorrhagia 0 0 1 0
Menorrhagia with
infrequent cycle
2 0 1 0
Menometrorrhagia 2 0 0 0
Polymenorrhoea 3 0 0 0
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Oligomenorrhoea 1 0 0 0
Total 22 1 4 3
Table-27: The 30% of patients with abnormal uterine bleeding73% of patients have normal TSH
levels. Among these 36.6% have complaints of menorrhagia and 27.7% polymenorrhagia.3% of
patients have TSH less than normal and is associated with menorrhagia.13.3% of patients have
mild elevation of TSH, here the commonest menstrual pattern being menorrhagia.10% have very
high TSH levels ,here too the commonest pattern being menorrhagia. Therefore total of 23% of
patients have high TSH levels.
Table-28: Distribution of menstrual patterns of patients according to T3 and T4 levels
Menstrual pattern T3 T4
Normal Abnormal Normal Abnormal
Menorrhagia 10 3 10 3
Polymenorrhagia 7 0 6 1
Metrorrhagia 0 1 1 0
Menorrhagia with
infrequent cycle
3 0 3 0
Menometrorrhagia 2 0 2 0
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Polymenorrhoea 3 0 3 0
Oligomenorrhoea 1 0 1 0
Table-28: The above table correlates T3, T4 levels with menstrual pattern. About 13.3% of
patients with abnormal uterine bleeding have abnormal T3, T4 levels , about 4 out of the total 26
patients. Among these 1patient had lower than normal value. The rest of the 3 had higher than
normal values.
From the above two tables it can be concluded that 3% of our patients have hyperthyroidism and
23% have hypothyroidism. But out of the 23%; 13% have only TSH values elevated but normal
T3 , T4 values, indicating that they have subclinical hypothyroidism. Rests of the 10% have
overt hypothyroidism. No cases of sub clinical hyperthyroidism were found.
Table-29: Distribution of patients according to percentage of anemic (mild, moderate,
severe) with menstrual pattern
Menstrual pattern Normal Less than 8
Anemia
8 to 10.9
Moderate
Anemia
11 to 11.9
Mild anemia
Menorrhagia 6 2 4 1
PolyMenorrhagia 2 1 3 1
Metrorrhagia 0 0 1 0
Results
103 | P a g e
Menorrhagia with
infrequent cycle
0 2 1 0
Menometrorrhagia 1 0 1 0
Polymenorrhoea 1 0 1 1
Oligomenorrhoea 1 0 0 0
Total 11 5 11 3
Table-29: The above table correlates anaemia with bleeding pattern.5 patients (16.6%) of
patients had severe anaemia. 11(36.6%) had moderate anaemia and 3 (10%) had only mild
anaemia. The rest of the 11 patients (36.6%) had not developed anaemia. The commonest
menstrual patterns associated with anemia are menorrhagia and polymenorrhagia, accounted for
by the excessive blood loss. Of the 19 anaemic patients 7 had menorrhagia and 4 had poly
menorrhagia.
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7. Discussion 
The present study carried out among 30 patients presenting with abnormal uterine 
bleeding in the age group of 15-45 years. 30 patients who presented to the gynecology 
department with complaints other than menstrual complaints were taken as controls. Patients 
with thyroid tomour, on antithyroid medications, h/o recent thyroid surgeries were excluded. 
Women with any reproductive tract malignancies, organic lesions of the genital tract, IUCD 
users and bleeding disorders were not included in the study. 
In the present study, maximum numbers of patients with abnormal uterine bleeding 
were in the age group of 41-45 years which accounted for 43.33%. But in the control group 
about 46.67% were in the age group of 31-40 years. This demonstrates an increasing 
incidence of menstrual abnormalities in the perimenopausal age group, probably due the 
increasing number of anovulatory cycles.  
In a study by K Padmaleela et. al. in 2011-2012 studied 83 patients in 
Vishakapatnam, of which 53% patients were within the older age group of 35-45 years. 
About 31.3% of patients were in the age group of   25-34 years, 33.3% of patients were in the 
age group of 31-40 years, 16%  in the age group of 21-30 years and 6% in the age group <20 
years.81
In both cases and controls an equal and maximum number of patients were 
housewives. 4 patients were students among the cases but only one student presented with 
complaints other than menstrual abnormalities. Most of the women in both cases and controls 
were married. 13.3 % of women among cases and 3% in controls were unmarried.  
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 There was more number of patients from lower middle class among cases 43% and 
among controls33%. No patients from poor socioeconomic status were present in this study. 
All among controls and most of the patients among cases were moderately built and 
nourished. Only one patient was poorly built and nourished among cases. There were no 
obese women in the present study. 
70% of the subjects in both cases and controls had no significant past medical and 
surgical history. Only very few patients in the cases had hypertension or bronchial asthma. 
One patient had PCOD. 
The previous cycles of the patients were compared with the cycles of the control. 
There was no significant difference in the previous cycle length among the two groups, but 
there was an increase in the number of days of flow among cases when compared with 
controls and the values were statistically significant. There may be a relation between present 
duration of flow and future progression to abnormal bleed. This may suggest a change in the 
action of normal haemostatic mechanism coming into play towards the end of a menstruation 
in those with future predisposition to abnormal uterine bleed. This may be due to an 
inadequate secretion of estrogen derived from the emerging cohort.  
In the present study 46.67% of controls and 20% of cases were nulliparous. 43.33% 
of women were para 2, 20% para 3 and both together were 63.33%. Uniparous women 
accounted for 16.67% of cases .In the study done by Pahwa. et. al., a majority of patients i.e. 
80% belonged to the group para 2 to 4, 4.12% were uniparous and 7% were nulliparous. In a 
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study by Pilli. et. al. 87% of patients with DUB were multiparous, 7% uniparous and 6% 
nulliparous. But in the present study 20% of women were nulliparopus.82 
Among patients with abnormal uterine bleeding, most had vaginal deliveries. This 
was a lot more than the percentage of vaginal deliveries in controls. The numbers of 
tubectomised patients among cases were less compared to controls. In the total study 
population, 36.67% of patients had unhealthy cervix and 23.33% had abnormal discharge. 
This highlights the importance of complete gynecological examination including per 
speculum examination in all patients presenting to the gynecology OPD, irrespective of 
symptoms, so that necessary evaluation can be done.  
The comparison of mean values of pulse rates of cases and control showed a 
significantly higher rate among cases, but blood pressure values seemed unaffected. This 
may be due to the anemia caused by the abnormal bleed, so also a comparison of the mean 
hemoglobin levels among cases and controls showed lower hemoglobin values in the cases, 
owing to the anemia caused by the abnormal uterine bleed, the correction of which is a main 
factor in management of abnormal uterine bleed. No significant difference was noted in the 
platelet counts and BT, CT ruling out thrombocytopenia and clotting factor defects in the 
present study. 
The mean T3, T4   and TSH values of all the control groups were within normal range. 
Thus all patients with normal cycles with normal flow were euthyroid. The mean TSH values 
were high and above the normal range in patients with abnormal uterine bleeding. The mean 
T3 and T4   values were also higher in cases than controls with respective p values of 0.02 and 
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0.04 which were statistically significant, thus inferring that thyroid dysfunction was more 
common in patients with abnormal uterine bleeding than in the control group.  
 In the present study menorrhagia was the commonest abnormal menstrual pattern 
among cases accounting for about 43.33%, followed by polymenorhagia 23.33%, 
menorrhagia with infrequent cycles10%, polymenorrhoea 10%, and rest of the patterns like 
menometrorrhagia 6.68%, metrorrhagia and oligomenorrhoea 3% each. Pilli.et.al. reported 
34% menorrhagia as the commonest complaint followed by profuse bleeding following 
various periods of ammenorrhoea 14% and polymenorrhoea in 11% of cases. Mehrotra. et. 
al., too showed an incidence of 54.2% of menorrhagia. Pahwa. et. al. observed an incidence 
of 50% of menorrhagia in patients with DUB, followed by polymenorrhoea 19% and 
menometrorrahgia in 18%. These studies on abnormal uterine bleed have findings results 
comparable to our study.24    
Table 30-Menorrhagia in abnormal uterine bleeding 
S. NO Study type Percentage (%) 
1. Present study 43.33% 
2. K Padmaleela et al 50.00% 
3. Mehrotia et al 54.20% 
4. Pahwa Sangeetha et al 50.00% 
5. Pilli et al 34.00% 
6. Sharma N  et al 70.00% 
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But in our study polymenorrhagia was the next frequent complaint in 23.33%, where as the 
second most frequent menstrual pattern varied in different studies. 
The most common menstrual pattern in hypothyroid patients in the present study was 
menorrhagia accounting as high as 57.13%. Hypothyroidism was also associated with 
menstrual patterns like polymenorhagia, metrorrhagia, menorrhagia with infrequent cycles 
each accounting 14.7%. In the present study menstrual patterns like oligomenorrhoea, 
polymenorrhoea and menometrorrhagia were not associated with hypothyroidism. 
K Padmaleela. et. al. studied abnormal menstrual patterns in hypothyroid patients. Similar to 
this study here 53.3% had menorrhagia, 13.3% had polymenorrhoea and another 13.3% had 
oligomenorrhoea, polymenorrhagia, hypomenorrhoes and ammenorrhoea in 6.7% of patients 
each. But Pahwa. et. al. demonstrated menorrhagia in as many as 78.94% of patients 
followed by polymenorrhoea in 10.5%, menometrorrhagia and metropathia haemorrhagica 
accounted for the rest of the cases (each 5.26%).81 But a study by Sharma Neelu.et.al. on 
patients presenting to the endocrinology department in Jammu and Kashmir showed that 
44.1% of the hypothyroid patients had normal cycles whereas menorrhagia was found 
in35.2% cases and polymenorrhoea in another 23.52%.22
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Table 31-menorrhagia in hypothyroid patients 
S. NO Author Name Percentage (%) 
1. Present study 57.13% 
2. K Padmaleela et al 53.3% 
3. Kaur et al 64.3% 
4. C Doifode et al 63.3% 
5. Menon and Barucha(menorrhagia and 
polymenorrhoea) 
46.15% 
6. Pahwa et. al. 78.94% 
From the findings of this study and other studies it may be suggested that thyroid 
dysfunction affects the haemostatic mechanisms involved in menstruation, as the menstrual 
pattern with excessive flow are the commonest patterns associated with thyroid dysfunction. 
Only 3% of patients had hyperthyroidism in the present study and the percentage of 
menorrhagia was100%. In the study conducted by Padmaleela.et.al, among hyperthyroid 
patients 42.8% had menorrhagia, 28.6% had polymenorrhoea and 14.3% of polymenorrhagia 
and hypomenorrhoea. Kaur.et.al. had 1 patient with hyperthyroidism who had presented with 
hypomenorrhoea.81 
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Table 32-menorrhagia in hyperthyroidism 
S. No Author Name Percentage 
(%) 
1. Present study 100% 
2. Pahwa et al 100% 
3. Padmaleela et al 42.80% 
4. Sharma N  et al 25.00% 
5. Menon and Barucha   17.00% 
6. Singh et al  09.00% 
In the study by Singh.et.al oligomenorrhoea was the commonest menstrual pattern 
63.6%. Menon and Barucha found oligomenorrhoea in 23.07% of cases .The study by 
Sharma N showed the commonest pattern as normal cycle (37.5%).83 
In euthyroid women too the commonest pattern was menorrhagia 36.6%. But 
hypothyroid patients showed a higher incidence of menorrhagia (57.13%). 100% of 
hyperthyroid patients had menorrhagia. The next common menstrual patterns were 
polymenorrhagia 27.27% and polymenorrhoea13.65% 
In the present study   the patients were grouped according to age as 41-45 years, 31-
40 years, 21-30 years, and 20 years and less. Hypothyroidism in these reproductive age group 
women were seen to increase with advancing age. 57.14% of patients with hypopthyrodism 
belonged to the age group of 41-45 years (perimenopausal age group).Hypothyroidism in all 
other age group were similar; 14.7% in each group. The sole patient with hypothyroidism in 
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the age group15-20 years was 20 years of age. This study had no hypothyroid patients in 
pubertal age group. In the study conducted by K. Padmaleela.et.al, out of the15 patients with 
hypothyroidism 66.67 % were in the age group of 35-45 years, 20% between 15-25 years, 
and 13.33% between 25-34 years.81 Sharma et. al. also reported a similar 64.7% in the age 
group of 35-45 years and a 20.58 %and 14.7% in the age groups of 25-34 years and 15-24 
years respectively.22 All the above studies show a similar report of increasing incidence of 
hypothyroidism with advancing age. But Pahwa.et.al reported a 52.60% of hypothyroidism in 
the age group of 31-40 years, only 31.6% in the age group of 41-50 years and 15.7% in age 
group of 20-30 years. The findings of this study were different, probably due to the fact that 
majority of patients in this study belonged to that age group of 31-40 years.24 
In this study out of the 30 patients with abnormal uterine bleeding, 13 patients had 
menorrhagia, of these 53.8% of patients were 41-45 years of age, 38.46 % between 31-40 
years and 7.6% were 21-30 years. No patients, under   20 years had menorrhagia. In the next 
most frequent menstrual pattern of polymenorrhagia, 42.85 % were 41-45 years, 28.57% 
were 21-30 years and the age groups of 15-20 years and 21-30 years had 14.28% of the 
patients each. Similarly in the study done by Sharma. N. et. al. the patients with DUB were 
divided into 2 categories –the menorrhagia , polymenorrhoea group and the  
oligomenorrhoea, hypomenorrhoea group. 50% of patients with DUB were in the 
menorrhagia polymenorrhoea group and in the age group of 35-45 years, 20% in the age 
group of 25-34 years and 8% 15-24 years. 10% of patients with DUB were oligomennorhoea 
hypomenorrhoea group and were 15-24 years, 8% 25-34 years and 4% 35-45 years of age.22
The study by Pahwa.et.al, showed a different pattern. 40% of patients with menorrhagia were 
31-40 years, 36% were>40 years, 24% were 20-30 years. The next frequent menstrual pattern 
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was menometrorrhagia, here too 61 % of them were 31-40 years. 22.2%41-50 years and 
16.6% 20-30 years. But in their polymenorrhoea group 42% were between 41-50 years. So 
also in patients with metropathia hemorrhagica 57% were 41-50 years. The major pattern of 
abnormal uterine bleeding in 15-20 year old patients was menorrhagia with infrequent cycles, 
probably due to the anovulatory cycles in the few years after menarche.24   
Table 33-distribution of patients according to thyroid status 
Thyroid
status 
Present
study
Pahwa et al Padmaleela 
et al 
Kaur et al  Neelu
Sharma et al 
Euthyroid 73.34% 76% 73.5% 85% 64% 
Hypothyroid 23.33% 22% 18.1% 14% 22% 
Hyperthyroid 3.33% 2% 8.4% 1% 14% 
The present study showed that thyroid dysfunction was present in 26.66% of patients 
presenting to the department of gynecology with abnormal uterine bleeding whereas 73.34% 
of patients were euthyroid. Hypothyroidism was 7 times more common than 
hyperthyroidism in the present study. Hypothyroidism was present in 23.33% of cases and 
hyperthyroidism in 3.33% of cases. The finding of this study was comparable to most other 
studies. 
Padmaleela.et.al. reported 73.15% of euthyroid patients, 18.10% of hypothyroid 
patients and 8.4% of hyperthyroid patients. Pahwa.et.al. also reported similar results of 22% 
of hypothyroid and 2% of hyperthyroid cases. Though Neelu Sharma reported similar 
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percentages of hypothyroidism, she had a much larger percentage of hyperthyroid patients, a 
14%. But study was carried out in the Sub Himalayan belt of Jammu.81 
In the present study, out of the 23% of patients who had hypothyroidism, 13% had 
subclinical hypothyroidism and 10% had frank hypothyroidism. In this study no cases of 
subclinical hyperthyroidism were found. In the study by Doifode et al, out of the 28.17% of 
patients with hypothyroidism 22.3% had subclinical hypothyroidism. In a similar study by 
Kundu et al, carried out in 100 patients, 13% of patients had sub clinical hypothyroidism.84
pIn the present study, 63.33% of patients with AUB had developed anemia .Most of 
the patients had Hb between 8-10.9 and around 16.6% had Hb <8.The most frequent 
menstrual patterns associated with anemia,were menorrhagia and polymenorrhagia; the ones 
with excessive flow. 
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8. Conclusion
The present study was conducted in patients in reproductive age group presenting with
abnormal uterine bleeding (cases) and in patients who presented with complaints other than
abnormal uterine bleeding (controls) and thyroid function evaluated in both groups.
Thyroid dysfunction was found to be much more prevalent in patients with
abnormal uterine bleeding (cases) than the controls.
Among the cases hypothyroidism was more common than hyperthyroidism.
Unless a proper evaluation of the thyroid function tests are done among these
patients,we are bound to miss the etiology of the abnormal bleed leading to
nonspecific and ineffective invasive and noninvasive procedures and treatment.
Hence thyroid profile should form an integral part in the evaluation of all patients
presenting with AUB and then correction of the thyroid function should be done for
efficient and effective treatment.
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9. Summary
The present study was carried out among 60 patients presenting to the department of
Gynecology. These patients were selected on the basis of inclusion and exclusion criteria. 30
patients with abnormal uterine bleeding were included in cases; remaining 30 patients with
complaints other than abnormal uterine bleeding were included in the control group.
The following observations were made from the present study
Most of the patients in control group were in the age group of 31-40 years whereas
among cases more number of patients were of 41-45 years.
In both groups most of the patients were house wives. Students were more among cases
(4) than the control (1). Maximum number of patients in both groups were married
There were more number of patients from lower middle class families among cases than
in the control group.
Most of the patients in cases and control groups had no significant past history and family
history.
The previous menstrual history of both cases and controls showed no significant
difference in age at menarche and previous cycle length but there was an increased in the
number days of flow among the cases. All the parous women in among the cases had
normal vaginal deliveries.
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36% of the study population had unhealthy cervix. 23% had abnormal discharge.
Cases showed higher pulse rate than controls and hemoglobin values were significantly
low. Blood pressure, platelet count, bleeding time and clotting time showed no significant
difference.
Serum T3, T4 and TSH levels were within the normal range for all the controls. The cases
showed significant difference in all the thyroid parameters.
43.33% of patients had menorrhagia and 23.3% had polymenorrhagia. Only 3% patients
had oligomenorrhoea.
The most common menstrual pattern in patients with hypothyroidism was menorrhagia
(57.13%). No patients had polymenorrhea, oligomenorrhoea and menometrorrhagia. The
patient with hyperthyroidism had menorrhagia.
Thyroid dysfunction both hypothyroidism and hyperthyroidism was more common in the
perimenopausal age group. Only one hypothyroid patient was found in the age group of
less than 20 years.
3% of patients had less than normal TSH levels and it was associated with menorrhagia.
23 % of patients had high TSH levels and was also associated with menorrhagia. 13% of
patients had subclinical hypothyroidism.
16.6% of patients had severe anaemia, 36.6% had moderate anaemia. The commonest
menstrual patterns among them were menorrhagia and polymenorrhagia.
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II
ABBREVIATIONS
AUB: Abnormal Uterine Bleeding
DUB: Dysfunctional Uterine Bleeding
T3 : Triiodothyronine
T4 : Tetraiodothyronine
TSH : Thyroid Stimulating Hormone
TBG : Thyroxine Binding Globulin
MIT: Monoiodothyronine
DIT: Di Iodothyronine
TRH: Thyrotropin Releasing Hormone
RIA: Radio Immuno Assay
SHBG: Sex hormone binding globulin
TFT: Thyroid Function Test
ELISA: Enzyme Linked Immuno Sorbent Assay
SPSS: Statistical Package for Social Sciences
iPROFORMA
Evaluation of thyroid profile in abnormal uterine bleeding patients
SERIAL NO: HOSPITAL NO. :
NAME: OCCUPATION:
AGE:
ADDRESS:
1. CHIEF COMPLAINTS:
2. HISTORY OF PRESENTING COMPLAINTS:
A) Bleeding per vagina:
Duration:
Interval:
Quantity: Scanty / Moderate /Excessive
H/o Dysmenorrhoea: Yes /No
B) Other complaints:
3. MENSTRUAL HISTORY:
Age of attainment of menarche:
Previous Menstrual cycles-
Duration of Cycles :
Amount of flow :
Duration of flow :
Associated dysmenorrhoea:
Date of last menstrual period:
4. MARITAL HISTORY:
5. OBSTETRIC HISTORY:
Married Life: Para: Living:
Abortion: Last Delivery:
Type of Deliveries: Tubectomy: Yes / No
6. PAST MEDICAL AND SURGICAL HISTORY:
TB / Thyroid disorders/ Bronchial asthma/ RHD/Blood transfusion / H/o Malignancies
and treatment details
H/o surgeries / H/o Antithyroid medication.
7. FAMILY HISTORY :
TB / Bronchial asthma / Diabetes mellitus / Hypertension / Genital malignancies /
Bleedeing disorders / Thyroid disorders
ii
8. PERSONAL HISTORY:
Diet:
Sleep:
Appetite:
Bowel:
Bladder:
9. SOCIO- ECONOMIC STATUS:
EXAMINATION OF PATIENT:
1. General examination
2. Nutritional Status
3. Pallor
4. Pulse rate
5. Blood pressure
6. CVS
7. Respiratory System
9. PER ABDOMEN:
Operative scar: Present / Absent
Engorged vein: Present / Absent
Ascites: Present / Absent
Any enlargement of
Liver / Spleen: Palpable / Non Palpable
10. VULVO VAGINA EXAMINATION: Healthy / Non Healthy
11. PER SPECULUM EXAMINATION:
12. BIMANUAL VAGINAL EXAMINATION:
13. PERRECTAL EXAMINATION:
14. INVESTIGATIONS:
Hb % Platelet count
Urine : Albumin: Sugar: Microscopy:
BT, CT
15. USG – ABDOMEN PELVIS
16. COMPULSORY
Thyroid function test: a) Serum free T3 b) Serum free T4 c) TSH
iii
CONSENT FORM
PARTICIPANTS CONSENT FORM
The details of the study have been explained to me in writing and the details have
been fully explained to me. I am aware that the results of the study may not be
directly beneficial to me but would help in the advancement of medical sciences. I
confirm that I have understood the study and had the opportunity to ask questions.
I understand that my participation in the study is voluntary and that I am free to
withdraw at tany time without giving any reason, without the medical care that will
normally be provided by the hospital being affected. I agree not to restrict the use of
any data or results that arise from this study provided such a use is only for
scientific purpose(s). I have been given an information sheet giving details of the
study. I fully consent to participate in the study titled “Evaluation of thyroid profile
in patients with abnormal uterine bleeding”.
Serial no / Reference no
Name of the Participant Address of the participant
Contact number of the participant
Signature / thumb impression of the participant / Legal guardian
Witnesses
1.
2.
Date:
Place:
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MASTER CHART
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1. Sothari 886488 32 M H L LAP 1. Sarala Devi 182919 43 M E U Menorrhagia
2. Asha 13238953 27 M H L PI 2. Sudhakumari 184320 45 M H U Polymenorrhagia
3. Lani 13136100 34 M E U PI 3. Mary 184895 38 M H L Metrrorhagia
4. Sasikala 13209185 32 M H U PI 4. Jayanthi 139239 25 M U L Menorrhagia
5. Sunitha 13198333 29 M E U SI 5. Kulsam
beevi
185290 45 M H U Menorrhagia
6. Fathima 131366 38 M H U DP/V 6. Saraswathi 14001478 28 M E L Menorhagia (with
regular and
infrequent cycles)
7. Sudha 13135122 32 M H L DP/V 7. Sasikala 13207288 31 M E U Menorrhagia
8. Supriya 13158426 20 UM S L MPA 8. Aryasree 13193395 15 UM S U Polymenrrhagia
9. Lalithambika 13216246 30 M E L PI 9. Thulasi 13170997 41 M U L Menometrorrhagia
10. Gomathy 13232647 39 M E U PI 10. Murugam 13157186 40 M H U Menorrhagia
11. Girija 212138 28 M H L SI 11. Basumathi 185188 27 M H U Polymenorrhagia
12. Thulasi 13208124 37 M H U SI 12. Sumathi 212738 32 M H U Polymenorrhoea
13. Nisha 191475 29 M H U SI 13. Mary Kripa 13208071 22 UM S U Polymenorrhoea
14. Brinalla 13177201 25 M Ul L PI 14. Naveena 13176623 20 UM S U Menorrhagia
( with regular
infrequent cycles
15. Selastin
Mary
255529 31 M E U PI 15. Shyla 13168803 43 M H L Polymenorrhagia
16. Anitha 13189268 35 M E U PI 16. Lalitha 13096756 45 M H L Polymenorrhagia
17. Vijaya
Surush
14004075 45 M H U BL 17. Jalaja 13108494 39 M H L Menorrhagia
18. Laly 060332 37 M H U RLAP 18. Nagalakshmi 13131614 36 M H U Menomrorrhagia
19. Chandra
Sheeba
172900 29 M H U SI 19. Beula 13182215 37 M E U Polymenorrhoea
20. Anitha M 14005929 33 M H U LAP 20. Thilakm 13210893 44 M H L Menorrhagia
21. Grace
Evangelin
181583 45 M H L DP/V,
LAP
21. Vasanthi 13171064 42 M H L Menorrhagia
22. Padmaja
Kumari
182278 45 M H U OC
(USG)
22. Sarojini 198606 45 M H U Menorrhagia
23. Usha 182270 43 M H U LAB 23. Kala 14002334 35 M U L Menorrhagia
24. Pavithra 182276 32 M H L PI 24. Santha
Kumari
14008928 43 M H L Menorrhagia
25. Vijayalaksh
mi
182237 44 M H U LAP 25. Mahalakshmi 14008978 38 M E L Polymenorrhagia
26. Ambika 188402 42 M E U LAP 26.
.
Menol 13210909 15 UM S U Menorrhagia(with
infrequent cycles)
27. Anjana 188463 42 M E U DIPU 27. Rethinam 13118109 42 M H U Menorrhagia
28. Shalini 188562 45 M H U DP/V 28. Suji Kumari 13192712 30 M H U Polymenorrhagia
29. Ranjani 188602 42 M U L LAP,
DP/V
29. Nirmala
Kumari
13081090 39 M H L Menorrhagia
30. Shusila 188635 36 M E U RLAP 30. Sarojini 14002289 45 M H U Oligomenorrhoea
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PREVIOUS MENSTRUAL HISTORY AND PAST OBSTETRIC HISTORY
Controls Cases
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1 15 30 MD 2 N 3 ND Yes Nil Nil 1 14 30 MD 4 N 2 ND Yes Nil Nil
2 12 30 MD 4 N 0 No No Nil Nil 2 12 35 MD 6 N 1 ND No HT DM,
HT
M
3 14 30 MD 3 N 0 No No Nil Nil 3 15 30 MD 7 N 3 ND Yes Nil Nil
4 14 30 MD 4 N 0 No No Nil Nil 4 13 28 MD 5 N 1 ND No AT Nil
5 15 30 MD 5 N 1 CS No Nil Nil 5 15 30 MD 8 N 1 ND No DM DM
6 14 27 MD 5 N 2 ND Yes Nil Nil 6 14 30 MD 6 N 1 ND No PCO
D
Nil
7 14 30 MD 3 Y 2 ND Yes Nil Nil 7 13 30 MD 8 Y 1 ND No Nil Nil
8 14 30 MD 6 Y 0 No 0 Nil Nil 8 13 25 MD 7 N 0 No No Nil Nil
9 16 30 MD 4 N 0 No No AT DM
HT
9 14 30 MD 4 N 3 ND Yes Nil Nil
10 15 30 MD 5 N 0 No No Nil Nil 10 15 35 MD 5 Y 3 ND Yes DM,
HT
Nil
11 14 30 MD 4 N 0 No No Nil HP
T
11 15 30 MD 5 Y 2 ND Yes Nil Nil
12 15 25 MD 4 N 0 No No Nil Nil 12 14 30 MD 4 N 2 ND Yes Nil Nil
13 13 30 MD 6 Y 0 No No Nil Nil 13 14 60 MD 5 N 0 ND No Nil Nil
14 13 30 MD 3 Y 0 No No Nil HT 14 12 30 MD 4 N 0 ND No Nil Nil
15 12 32 MD 3 Y 0 No No AS LP,
AS
15 16 28 MD 5 Y 2 ND Yes AT AT
16 16 30 MD 4 N 0 No No Nil Nil 16 16 28 MD 4 N 2 ND Yes Nil Nil
17 16 25 MD 4 N 1 ND No BL HT 17 14 30 MD 3 N 2 ND Yes Nil Nil
18 13 30 MD 5 Y 2 ND Yes OC DM
,HT
18 14 30 MD 4 N 2 ND Yes Nil Nil
19 13 30 EX 4 Y 0 No No EP,
LP
Nil 19 15 30 MD 4 Y 2 ND Yes Nil Nil
20 13 30 MD 4 Y 2 ND Yes DM Nil 20 13 30 MD 5 Y 3 ND Yes Nil DM
21 15 30 MD 4 N 1 ND No HT,
PT
Nil 21 14 30 MD 3 Y 2 ND Yes DM,
HT
Nil
22 14 30 MD 2 Y 2 CS No Nil Nil 22 14 30 MD 4 Y 3 ND Yes Nil Nil
23 16 30 MD 4 Y 2 ND Yes Nil Nil 23 14 30 MD 4 Y 2 ND Yes Nil DM
24 13 30 MD 4 Y 0 No No Nil Nil 24 14 30 MD 6 Y 3 ND Yes Nil Nil
25 15 26 MD 5 N 2 CS Yes AT Nil 25 14 30 MD 7 Y 0 No Yes AT DM,
AT
26 13 28 MD 5 Y 2 ND Yes Nil HT 26 14 30 MD 8 N 0 No No Nil Nil
27 13 32 MD 5 N 2 ND Yes Nil Nil 27 14 28 MD 7 Y 2 ND Yes Nil Nil
28 14 32 MD 4 N 1 ND No AD Nil 28 15 28 MD 5 N 2 ND Yes Nil Nil
29 12 30 MD 4 N 1 CS No Nil Nil 29 12 30 MD 3 N 2 ND Yes AD DM,
HT
30 14 30 MD 5 N 2 ND Yes Nil Nil 30 11 60 MD 5 N 0 No No Nil DM
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Control Cases
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1. PA MD 70 110 70 1. PA MD 76 110 70
2. PA MD 80 100 60 2. PA, DS MD 78 150 100
3. NL MD 72 120 80 3. PA Poor 76 100 60
4. PA MD 72 110 90 4. PA, DS MD 88 110 60
5. N MD 72 110 70 5. PA MD 78 120 80
6. PA MD 70 120 70 6. PA, DS MD 78 110 70
7. NL MD 70 100 70 7. DS MD 72 110 70
8. NL MD 70 100 80 8. PA MD 92 100 60
9. NL MD 78 120 80 9. PA MD 70 110 80
10. NL MD 72 120 70 10. PA MD 80 110 70
11. NL MD 70 110 70 11. PA MD 70 120 80
12. PA MD 72 110 70 12. PA MD 70 100 70
13. NL MD 72 110 70 13. NL MD 78 110 90
14. NL MD 76 120 80 14. PA MD 80 110 70
15. MD 72 120 80 15. PA MD 69 110 90
16. MD 72 100 60 16. PA MD 72 110 80
17. PA MD 72 130 70 17. PA MD 72 120 70
18. PA MD 84 110 70 18. PA MD 76 110 70
19. PA MD 72 120 70 19. PA MD 70 100 90
20. MD 72 120 80 20. PA MD 88 130 90
21. PA MD 72 130 90 21. PA MD 80 120 70
22. MD 72 120 80 22. DS MD 78 120 90
23. MD 76 120 80 23. MD 72 120 90
24. MD 74 124 82 24. PA MD 88 100 60
25. PA MD 80 120 84 25. PA MD 72 130 90
26. MD 72 120 80 26. PA MD 88 110 60
27. MD 74 128 78 27. PA MD 72 110 80
28. MD 68 122 78 28. PA MD 72 100 60
29. MD 74 120 80 29. PA MD 70 120 70
30. MD 78 120 78 30. MD 72 110 70
xCLINICAL INVESTIGATIONS DATA OF CONTROL AND CASES
Control Case
S.
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H
1. 13 3 2 4 4.45 11.98 3.58 1. 13.1 3 1:30 4:30 4.24 18.73 3.04
2. 9.4 3.2 2 5:30 3.82 11.56 4.5 2. 9.7 2.9 2:30 4:10 3.28 6.85 32.89
3. 12.6 3 2 3:45 3.41 18.60 2.62 3. 9.4 3.2 2:30 0:30 1.90 15.25 6.73
4. 11.6 3.2 1:30 4:30 3.50 11.37 2.97 4. 10.0 4 1:30 3:00 3.85 8.85 31.4
5. 13.2 4.1 1:30 4 3.52 15.97 1.85 5. 12.5 3.8 1:45 4:20 6.42 19.14 5.78
6. 10 3 1:15 3 5.05 15.00 3.87 6. 9.7 2.7 1:46 4:35 4.59 10.52 1.09
7. 12.7 3.8 2:30 6:30 4.44 15.15 2.05 7. 13.2 4.02 1:30 4:30 3.09 14.10 4.23
8. 11.8 3.8 1:45 4 4.24 19.02 2.35 8. 6.90 4.02 3:30 4:30 5.03 14.23 3.58
9. 12.3 3.8 2:15 3:30 3.5 17.3 9.0 9. 10.6 3.94 1:30 4:00 2.40 18.20 4.80
10. 13.1 4 2 5:30 5 12.07 3.1 10. 8.2 3.96 1:45 3:30 1.03 7.9 15.61
11. 13.2 4 1:30 4:30 4.22 17.7 1.91 11. 11.5 3.4 1:30 6:00 3.75 15.29 1.31
12. 10.6 3.4 1:13 3:30 3.32 11.88 2.63 12. 11.5 3.84 3:00 5:51 4.48 12.18 3.58
13. 11 2.8 1:30 4:30 3.94 17.56 2.21 13. 12.0 3.82 3:56 4:28 4.19 14.89 2.69
14. 12.8 3.54 1:30 5 4.76 17.67 3.58 14. 4.9 4.52 2:86 3:29 3.25 13.61 17.83
15. 12 4 1:30 3:30 2.94 15.41 1.39 15. 8.9 4 2:1 3:45 3.47 17.50 0.66
16. 12.6 3.4 1:50 5:30 3.84 20.16 1.49 16. 10.8 3.67 3:48 4:08 3.70 14.24 4.77
17. 9.3 3.67 1:45 3:30 4.63 15.42 3.63 17. 11.8 3.8 1:30 4:00 5.29 18.84 2.52
18. 11 3.48 1:45 5 4.2 12 3.6 18. 12.8 3.24 1:30 4:00 3.29 10.48 1.56
19. 12.6 3.45 1:30 3:30 4 11.8 4.6 19. 10 3.9 1:30 4:30 4.08 18.25 1.45
20. 12.2 4 1:45 3:45 2.71 14.08 1.47 20. 9.90 3.6 3:56 4:21 3.31 16.01 1.79
21. 13.6 3.2 3:30 6 4.08 12.33 2.14 21. 6.1 3.02 2:86 3:08 10.92 40.27 0.01
22. 13.1 4 3 5 3.84 14.92 2.8 22. 12.9 3.98 1:30 4:30 3.45 13.20 18.60
23. 11.4 2.48 1:45 3:48 3.92 16.74 2.23 23. 12.8 4 3:56 4:21 3.21 12.86 1.01
24. 12 3.48 1:30 3:30 2.8 15 1.4 24. 3.3 2.14 1:08 1:45 5.00 12.67 0.87
25. 9 3 1:04 3:03 4.4 15 3.8 25. 11.8 2.84 1:30 4:00 2.77 13.71 0.43
26. 11 3.2 1:04 3:05 3 12 4.6 26. 8.0 4.18 1:45 4:00 5.03 20.78 1.12
27. 12 3.2 2 3:08 4.4 14.2 2.8 27. 12.0 3.94 1:30 4:30 3.64 18.70 1.40
28. 12.8 3.6 3:28 5:02 3.2 14 4.2 28. 12.0 3.84 3:49 4:26 4.31 18.11 3.06
29. 11.8 3.68 3 4:08 4 12 4.4 29. 10.8 3.6 1:30 5:00 1.44 3.97 42.72
30. 12 3 2 3:04 4 14 3 30. 14.5 3.24 1:30 5:00 4.16 16.55 1.45
KEY TO MASTER CHART
[O- OCCUPATION, SCS – SOCIOECONOMIC STATUS, LAP – LOWER ABDOMINAL PAIN, PI – PRIMARY INFERTILITY, SI –
SECONDARY INFERTILITY, M – MARRIED, UM – UNMARRIED, H – HOUSE WIFE, E – EMPLOYED, S – STUDENT, U – UPPER
MIDDLE CLASS, L – LOWER MIDDLE CLASS, MD – MODERATE, PH – PAST HISTORY,FH – FAMILY HISTORY, MD –
MODERATE, EX – EXCESSIVE, ND – NORMAL DELIVERY, CS – CAESAREAN SECTION,Y – YES,N – NO,DM – DIABETES
MELLITUS, HT-HYPERTENSION,AT – ASTHMA,PA – PALLOR,NL – NORMAL, SBP– SYSTOLIC BLOOD PRESSURE, DBP –
DIASTOLIC BLOOD PRESSURE, PR – PULSE RATE,HB – HEMOGLOBIN,PC – PLATELET COUNT,BT – BLEEDING TIME,CT –
CLOTTING TIME]
